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ABSTRACT
Highly active antiretroviral treatment (HAART) has transformed the state of
human immunodeficiency virus (HIV) from acute to chronic. As a result, the long-term
effect of HAART has caused weight gain among HIV-infected individuals, leading to an
increased prevalence of overweight and obesity. Increased Body Mass Index (BMI) has
been associated with adverse health outcomes in non-HIV and HIV populations, yet
among HIV-infected individuals, a higher BMI at diagnosis offers a slower progression
from HIV to AIDS. Pre-HAART, studies reported that obese HIV-infected individuals
have higher increases in CD4 count over time. However post-HAART, some report that
overweight HIV-infected individuals with a higher BMI experience increased CD4
counts. In addition, HIV-infected treated individuals are now experiencing cardiovascular
disease outcomes. Therefore, additional research is needed to support current evidence.
Given that our study population consists of individuals from South Carolina, a state with
a high prevalence of HIV and obesity, it is beneficial to explore the relationship between
BMI at diagnosis and markers for HIV progression and cardiovascular disease risk. This
cohort study consisted of 396 HIV-infected adults from the Ryan White Clinic in SC. The
objectives of this study were to evaluate the relationship between BMI at diagnosis and
CD4 count over time, to evaluate this relationship by gender, and to evaluate the
relationship between BMI at diagnosis and cardiovascular disease risk markers (highdensity lipoprotein(HDL), low-density lipoprotein (LD), systolic blood pressure (SBP),
diastolic blood pressure (DBP), and fasting blood glucose).
v
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CHAPTER 1
INTRODUCTION
In HIV infection, CD4 count is used to determine treatment and monitor
progression of HIV.1 2 3 It also serves as the most important prognostic factor that
correlates the most with disease progression. Furthermore, CD4 count also is associated
with the risk of cardiovascular disease among HIV patients.4 5 6 While the relationship
between disease progression and CD4 has been proven, other factors such as HIV-RNA
viral load, mode of transmission, age, gender and race also have been determined to be
associated with disease progression.7 8 9 10 11 12 13 14 15 Recent evidence suggests that
nutritional status also impacts disease progression and the development of complications
but this has not been extensively researched.
Body mass index (BMI) is an anthropometric indicator computed from height and
weight and has been used to predict survival in non-HIV patients.7 17 18 Those considered
to be underweight (BMI<18.0) or obese (BMI≥30) are at higher risk of acquiring
infections such as pneumonia, bacteraemia and lower respiratory infections.18 A
systematic review reported that obese individuals with infections had worst outcomes
compared to the other BMI categories.18 It is well documented that obesity leads to
adverse health outcomes such as cardiovascular disease, diabetes, cancer and mortality.19
Among HIV patients, those obese tend to have higher CD4 levels and lower HIV-RNA
viral loads. A possible explanation of this effect is that the increased levels of leptin in
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obese individuals, increases T-cell proliferation.20 Since viral load has an inverse
relationship with CD4 T-cells, it is possible that as CD4 count increases, viral load will
decrease as a response to the relationship between leptin and CD4 T-cells. Those
considered being underweight and malnutrioned at the time of starting treatment were
associated with increased risk of survival. 20 Given obesity’s effect on the immune
system, it is logical to determine the association of BMI on progression of HIV. As the
data needed to compute BMI are relatively easy and inexpensive to collect, it can be
efficient to use BMI as an indicator to predict HIV progression.
Previous research on BMI and HIV disease progression has produced mixed
results. Obese HIV patients during the pre-highly active antiretroviral therapy (HAART)
era were seen to have a better survival rate or slower progression to AIDS compared to
normal weight HIV patients as well as those who experienced the "wasting syndrome."21
Studies have showed that HIV individuals who were obese at diagnosis have a decreased
risk of disease progression and better survival compared to other BMI categories.7 17 21 22
23 24 25

Obese HIV individuals at diagnosis also reportedly have higher CD4 counts and

lower HIV-RNA viral loads over-time. HIV individuals with increasing BMIs over-time
also have been associated with a decreased risk of disease progression. However during
the era of HAART, recent studies report that the protective effect of obesity may no
longer exist. It was reported that obese HIV patients now experience smaller increases in
CD4, concluding that obesity may actually provide more harm to HIV patients. 26 27 There
is limited evidence in this area of HIV, particularly in the era of HAART, and this study
will provide a longitudinal analysis of this association.
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As a result of the development of metabolic risk factors such as obesity, among
HIV patients, the risk of cardiovascular disease (CVD) has increased. 21 After the
initiation of HAART, more HIV patients became obese, leading to an increased chance of
developing cardiovascular outcomes. 21 One study reported that BMI was useful in
predicting CVD risk among their HIV population.28 Using hsCRP, an established
predictor of future coronary events, it was discovered that higher hsCRP levels were
associated with higher BMIs, higher low-density lipoprotein (LDL) and triglyceride (TG)
levels, and lower high-density lipoprotein (HDL) levels. However, they were limited due
to the small sample size. Given the increased risk of CVD outcomes in non-HIV obese
individuals, it is important to study this association among obese HIV individuals. One
serum marker used to determine risk of CVD is cholesterol. In non-HIV patients, lower
HDL levels and higher LDL and TG levels are associated with increased risk. 29 Among
HIV patients, studies report that lower CD4 counts and higher HIV-RNA viral load at
diagnosis are both associated with lower HDL levels and higher LDL and TG levels.4 6
Among HAART naïve HIV patients, higher BMI was associated with higher total
cholesterol. However, this association is higher among HAART treated HIV patients. 4 6
It is unclear whether BMI was measured at diagnosis or followed over-time.
To our knowledge, only five cohort studies (Boston, France, Miami, Nashville,
and West Africa) have been conducted to determine how well baseline BMI predicts HIV
disease progression.17 22 23 24 25 These studies populations consisted of HIV individuals
who were from sub-Saharan Africa17 , drug abusers22, public hospitals patients from
France23, only women.24, and those from an outpatient clinic in Nashville, TN.25 Two of
the studies used HIV-naïve patients as controls 22 24, while the other studies consisted of
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only HIV patients.17 23 25 These studies mainly focused on the association of BMI and
mortality and determined that BMI was a strong predictor of survival among HIV. While
these studies predicted survival and used certain AIDS defining events (e.g. first CD4 cell
count <200 cells/mm3) as outcomes, our study will focus on the longitudinal analysis of a
marker of HIV progression (i.e. CD4 count) as our outcome. Some studies have used
BMI as a time-dependent variable when determining the association with markers of
disease progression.20 21 22 24 25 30 31 32 However, this study will observe between disease
progression and BMI at diagnosis. It is important to determine whether BMI at diagnosis
has an association with markers of cardiovascular risk, as previous results have been
inconclusive.34 35 36 37 38 39 40 41 42 Recently, Koethe et al. discovered that patients classified
as overweight may promote optimal immune reconstitution (i.e. higher levels of CD4)
within 12 months of diagnosis once on HAART compared to those obese.25 Therefore, it
will be interesting to see if those results are repeated in the current study.
Data regarding the prognostic use of BMI in HIV patients are limited. The current
study will help to clarify the prospective association between obesity and disease
progression among HIV patients and, and the development of cardiovascular disease risk
markers in this population. The results of this study will help clinicians gain a clearer risk
profile of the HIV patient for more effective monitoring. The specific aims of this
proposal are as followed:
Aim 1: To determine the association between BMI at diagnosis and a marker of disease
progression (CD4 T cell count) over time.
Research Question 1.1: Is there a difference in mean CD4 between BMI
categories?
Research Question 1.2: Do HIV patients who are obese at baseline have a
slower progression of HIV (Higher CD4 T cell count) over time compared to
those in the normal BMI categories?
4

Aim 2: To determine whether the association between BMI at diagnosis and a marker of
disease progression (CD4 T cell count) over time differ by gender.
Research Question 2.1: Does the association between baseline BMI and disease
progression over time (CD4 T cell count) vary by gender?
Aim 3: To determine the association between BMI at diagnosis and markers of
cardiovascular disease risk (fasting blood glucose, HDL, LDL, SBP, and DBP) over time.
Research Question 3.1: Is there a difference in mean fasting blood glucose,
mean HDL, mean LDL, mean SBP, and mean DBP between BMI categories?
Research Question 3.2: Do normal weight HIV patients at baseline have lower
levels of these cardiovascular risk markers over time compared to obese HIVpatients?
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CHAPTER 2
LITERATURE REVIEW
2.1

What is HIV?
The human immunodeficiency virus (HIV) is a sexually transmitted disease that

leads to acquired immune deficiency syndrome (AIDS), the later stage of the HIV
infection.1 There are two different types of HIV are HIV-1 and HIV-2. In the United
States (U.S.), HIV is primarily referred to only HIV-1.1 HIV is spread by contact with
infected blood through unprotected sex, the sharing of needles, from mother to child
during pregnancy, childbirth, or breastfeeding.1 HIV destroys specific blood cells called
CD4+ T cells, also known as “helper cells”, which are essential in helping a person’s
body fight diseases.1 Once the immune system is weakened, the body’s ability to fight
organisms is diminished, leading to a greater chance of developing AIDS.
Several complications are related to the HIV infection. These include
opportunistic infections such as tuberculosis, candidiasis, pneumonia, toxoplasmosis,
kaposi’s sarcoma, herpes simplex, and tuberculosis.1 Other complications include
different forms of cancer, lipodystrophy as well as chronic wasting. These infections can
occur at different stages of HIV. People without HIV are also at risk of acquiring these
infections. However, these infections occur at a higher rate and it takes longer to recover
in those with HIV.1
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2.2

Epidemiology of HIV/AIDS
2.2a

Global

The number of people living with HIV worldwide has increased since its
discovery. The number of people living with HIV increased from roughly 9 million
people in 1990 to a total of 33.3 million people in 2009, with approximately 1.8 million
deaths due to AIDS.43 The majority of people living with HIV reside in Sub-Saharan
Africa (68%), South and South-East Asia (12%), North America (5%), and Central and
South America (4%), respectively. 43 A total of 2.6 million people were newly infected
with HIV worldwide in 2009, with the majority being adults (85%). 43 The Joint United
Nations Programme on HIV/AIDS reported that over 7000 new HIV infections occurred
per day in 2009, with roughly 97% of those infections being mostly women (51%) and
occurring in low and middle income countries.44
2.2b

United States (U.S.)

The prevalence of HIV among people in the US was estimated to be
approximately 1.1 million persons in 2006, with approximately 21% being undiagnosed. 1
The Centers for Disease Control and Prevention (CDC) reported that approximately
56,300 people were newly infected with HIV in 2006. 1 The majority of those new HIV
cases (53%) occurred in men who have sex with men (MSM). 1 MSM account for nearly
half of people living with HIV (48%), while heterosexuals account for only 25%.26
African Americans account for 46% of people living with HIV in the US as well as 45%
of new HIV infections. 1 The HIV incidence rate for African American men and women
was 7 times higher than their Caucasian counterparts. 1 Hispanics/Latinos represent 15%
7

of the population but account for an estimated 17% of people living with HIV and 17% of
new infections. 1
2.2c

South Carolina (SC)

In their 2007 surveillance report, the CDC reported that the Deep South (i.e.
Alabama, Florida, Georgia, Mississippi, Louisiana, North Carolina, and South Carolina)
were disproportionately affected by the HIV/AIDS epidemic. 1 In 2008, South Carolina
was ranked 10th in the US in AIDS cases, with a rate of 15.5 per 100,000 persons. 1 South
Carolina also ranked 7th in AIDS cases among females in the US, with a rate of 13.0 per
100,000. 1 The epidemic continues to increase in South Carolina with an average of 65
cases of HIV infections reported each month in 2009. 1 Furthermore, South Carolina has
experienced a 52% increase in people living with HIV/AIDS from 1999 to 2009. 1 People
who live with HIV in South Carolina are mostly men (69%), African American (73%),
aged 20-44 (42%) and MSM (44%).1 45
2.3

Predictors of progression in HIV
HIV is broken down into four distinct stages: primary infection, clinically

asymptomatic stage, symptomatic HIV infection and progression from HIV to AIDS. 1
Stage one, the primary infection stage, lasts for a few weeks and diagnosis is frequently
missed. During this stage, the immune system begins to respond to the HIV in the blood,
producing HIV antibodies and cytotoxic lymphocytes, which is known as seroconversion.
Stage two represents the clinically asymptomatic stage and generally lasts for an average
of ten years. HIV antibodies are detectable in the blood and diagnosis is usually evident
during this stage. Stage three is the symptomatic HIV infection stage whereby the
8

immune system has become severely damaged. HIV also has mutated allowing for
further destruction of the CD4 T-helper cells, which are needed to fight infection.
Furthermore, symptomatic HIV is usually caused by the opportunistic infections
described earlier. Finally, Stage four represents progression to AIDS which is caused by
the low count of CD4 T-helper cells and the increased number of severe opportunistic
infections.
Throughout HIV, there are several determinants that can be used to determine the
progression HIV.7 These determinants include immunological factors such as CD4+ T
cells and CD8 T-lymphocytes, virological factor such as HIV-RNA viral load, and other
factors such as age, gender, mode of transmission and body mass index. An
understanding of these factors is essential in guiding patient management and treatment.
While some of these prognostic factors are typically used to initiate treatment, track the
progression of HIV infection (e.g. CD4 count and HIV-RNA viral load) and monitor
response to treatment, others (e.g. BMI) are not used as much and could also possibly
assist in tracking the progression of the disease and providing the best methods in treating
each HIV patient. This could ultimately lead to a greater chance of survival.
2.3a

CD4+ T-cells

Known as the most significant predictor of disease progression and survival in
HIV patients, CD4 T-cell count takes precedent over any other predictors that are used
when treatment guidelines are recommended.2 3 7 CD4 T-cells are essential to the immune
system as they serve as signals that activate the immune’s response to organisms such as
viruses and bacteria. HIV attaches to and infects the CD4 T-cells. Over the course of
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HIV, CD4 T-cell count begins to decline. As a result, it is important that CD4 T-cell
counts are maintained within the normal range, which is 500-1000 cells/mm3. Treatment
is generally recommended when a HIV patient’s CD4 T-cell is ≤350 cells/mm3 and when
patients are in Stage 3 and 4 of the disease, irrespective of CD4 count.1 3 4 Once the cell
count is less than 200 cells/mm3, the patient’s immune system is severely weakened. This
leads to a greater risk for developing HIV-related complications and opportunistic
infections, including progression to AIDS.
Many studies have shown that CD4 count is highly associated with HIV
progression.2 7 8 46 47 The CASCADE collaboration reported that lower CD4 counts were
associated with a greater risk of disease progression, with the greatest risk occurring as
CD4 counts fall below 200 cells/mm3.48 This remains true when stratified by age. Van
Leth et al. determined that baseline CD4 T-cell count is predictive of virological failure.46
They showed that CD4 T-cell counts below 200 cells/mm3 at time of HAART initiation
are associated with an increasingly worse prognosis.47
2.3b

CD8 T-cells

CD8 T-cells, also called cytotoxic T-lymphocytes, are white blood cells that find
and destroy infected cells in the body.1 7 In the case of HIV, CD8 T-cells are activated by
CD4 T cells. It is thought that the anti-HIV specific CD8 T-cells are responsible for the
demise of the infected CD4 T-cells, further increasing in response to ongoing viral
replication. Evidence suggests that low absolute numbers of CD8 T-cell count correlate
with poor survival outcomes in HIV patients.7
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2.3c

HIV-RNA viral load

HIV-RNA viral load is the second most important marker used to determine
response to treatment.3 7 In most HIV patients, HIV-RNA viral load has an inverse
relationship with CD4 T-cell count. Higher HIV-RNA viral loads are correlated with a
rapid decline of CD4 T-cells. 3 7 A four-fold increase in the risk of AIDS can be detected
when HIV-RNA viral load is between 3000 copies/mL and 300,000 copies/mL, which
also is seen when stratified by age groups.7 In addition, there is an increase in risk of
disease progression in HIV patients with HIV-RNA viral loads greater than 100,000
copies/mL across all age and CD4 T-cell strata. 7
Higher HIV-RNA viral loads at diagnosis have been associated with faster CD4
T-cell decline over the first two years of infection.2 7 Some evidence has suggested that
HIV-RNA viral load serves as a better marker of disease progression when measured at
later times than at diagnosis.3 7 However, HIV-RNA viral load at diagnosis assists in
providing treatment to HIV patients earlier. Van Leth et al. reported that treatment
response was strongly related to HIV-RNA viral load at diagnosis, with HIV patients
whose HIV-RNA viral loads that were greater than 100,000 copies/mL at diagnosis
experiencing more virological failure after 48 weeks of treatment.46 According to recent
treatment guidelines, HIV-RNA viral load is only used to detect response to treatment
and not to monitor progression of HIV.3
2.3d

Age

Research has shown that as HIV patients get older, their risk of AIDS increases.7
Age at seroconversion has been found to have significant impact on the future
11

progression of HIV. Previous studies found an age effect correlating with CD4 count and
HIV-RNA viral load across all exposure categories.8 49 Some have suggested that since
older age is associated with lower CD4 counts at similar time from seroconversion, it
may explain the relationship between age and HIV progression.7 8 However, when HIV
patients are on HAART, the age effect at seroconversion is attenuated.
2.3e

Gender

Mixed results have been reported on the relationship between gender and HIV
progression. Some studies report that gender differences in HIV disease progression has
become larger and statistically significant in the era of HAART.7 8 9 13 14 15 16 Women tend
to have a higher HIV-RNA viral load at diagnosis compared to men, while HIV-RNA
viral load over-time has reportedly varied.7 9 10 Women also reportedly had an increased
risk of death even after adjustment for HAART use. 7 9 10 Low levels of CD4 T-cells (<50
cells/mm3 ) were found to be associated with higher HIV-RNA viral loads in women than
in men within the same CD4 count.9 Conversely, at higher CD4 T-cell levels (>350
cells/mm3), mean HIV-RNA viral load has been noted to be lower in women compared to
men in the same CD4 stratum.8 Despite the variation in HIV-RNA viral load, disease
progression has not been seen to differ between genders for CD4.7 11 One study reported
that disease progression was similar between genders. 11 Currently, there is no sexspecific treatment guideline for the initiation of treatment.3
2.3f

Race

Research that has focused on the relationship between race and HIV progression
has discovered that race mainly does not have an impact on the progression of HIV,
12

which is independent of confounders such as psychosocial factors, access to care and
genetically driven response to therapy.7 However, three studies discovered a difference
between race and HIV disease progression.12 14 16 Lemly et al. reported that the African
Americans had an increased risk of death compared to Caucasians.14 However, this
association was no longer seen after adjustment for HAART use. Smith et al. reported
that HIV-RNA viral load was discordantly low in African Americans compared to
Caucasians stratified for CD4 count.12 Finally, Meditz et al. reported that Non-Caucasian
women were most likely to experience an HIV/AIDS related event compared to others (p
= .035), even after adjustment for intravenous drug and HAART use.16
2.3g

Mode of Transmission

Contradictory results have been reported on the effect of mode of transmission on
HIV disease progression. An earlier study reported that homosexuals had a significantly
faster progression compared to heterosexuals.50 However, a recent study found no
difference in disease progression between the different modes of HIV transmission.51 It is
important to note that injected drug users do have other-cause mortalities, which could
confound the results of a study. This was seen in the CASCADE collaboration study
where they determined in the post-HAART era, homosexual and heterosexual risk groups
have a reduction in mortality, while no change was seen among injected drug users.48 The
higher risk in injected drug users can be due to lack of adherence to treatment and lack of
access to treatment.
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2.3h

Body Mass Index (BMI)

Body mass index is a simple predictor that has been recently used to determine
progression of HIV.7 The association between BMI and HIV progression is important for
two reasons. First, the “wasting syndrome”, which is involuntary loss of more than 10%
of body weight including more than 30 days of diarrhea, weakness, or fever, is
considered an AIDS defining illness according to the CDC classification of disease.1
Secondly, the simplicity of measuring BMI allows it to serve as a highly useful marker
for the initiation of treatment in resource-limited countries. Past research has shown that
long-term monitoring of BMI is predictive of disease progression.7 20 21 22 23 24 25 A rapid
decline in BMI among HIV patients has been shown six months preceding the diagnosis
of AIDS.7 24 Those considered underweight at diagnosis have been shown to be predictive
of increased mortality, even in racially diverse cohorts.7 17 One study discovered that a
BMI < 17 kg/m2 six months after initiation of treatment has been associated with a twofold increase in risk of death.6 Furthermore, a BMI < 18.5 kg/m2 shows similar utility to
CD4 count and HIV-RNA viral load based guidelines for the initiation of treatment. 7
Given these associations between BMI and survival among HIV patients, as well as
BMI’s correlation with infection in non-HIV patients18 , BMI may prove to be a valuable
predictor for disease progression in HIV patients.
2.4 Predictors of cardiovascular related outcomes among HIV patients
During the early years of HIV/AIDS, the “wasting syndrome” was once the
hallmark of HIV/AIDS.1 21 Pronounced loss of weight, lean body mass and fat mass were
attributed to an array of factors including opportunistic infection, living below the
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poverty level, low CD4+ cell count and high viral load.1 Today, HAART has transformed
HIV disease into a chronic illness, which has caused incidence of wasting to decrease and
the rates of obesity to increase.
People living with HIV are gaining weight and beginning to approach weight
levels seen in the general U.S. population. Approximately two out of every three adults
are overweight (i.e. BMI = 25-29.9) and one in every four adults are obese (i.e. BMI≥30)
in the US.21 Six states, including South Carolina (30.1%) had a prevalence of obesity
equal to or greater than 30% in the general population.19 Some studies have reported a
lower prevalence of obesity among HIV-infected populations versus the general
population,52 53 whereas others have reported a higher prevalence .24 54 Although the
effect of HAART in causing obesity in HIV-infected patients may quantify the relatively
slower progression to AIDS and provides the survival advantage afforded by elevated
BMI,24 certain problems have arose that has caused researchers question the mechanistic
role of HAART.
Shortly after the introduction of HAART, several new metabolic abnormalities
were reported and linked to its use.55 Overweight and obesity are considered to be
primarily responsible for the rising prevalence of these abnormalities. When taken
together, these abnormalities form what is called the metabolic syndrome, which is seen
in both non-HIV and HIV patients. Components of metabolic syndrome typically include
abdominal obesity, hyperlipidemia, hypertension and diabetes.56
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2.4a Cholesterol
Cholesterol is a waxy, fat-like substance that occurs naturally in the body.57
Cholesterol is needed for the body to work properly, but if too much is in the blood, it can
lead to plaque build-up in the arteries. This can lead to increased risk of developing heart
disease, stroke, and other cardiovascular disease outcomes.
There are three types of cholesterol: Total Cholesterol (all cholesterol combined),
High density lipoprotein (HDL) cholesterol (known as the good cholesterol), and Low
density lipoprotein (LDL) cholesterol (known as the bad cholesterol). 57 Low levels of
HDL combined with high levels of LDL and triglycerides indicate high cholesterol or
what is better known as hyperlipidemia. Generally, high cholesterol levels are caused by
unhealthy lifestyles, being overweight as well as certain medications such as diuretics
and beta-blockers. 57 Approximately one in every six adults (~16%) of the U.S. adult
population have high total cholesterol (> 240 mg/dL), with Hispanic men and Caucasian
women displaying the highest levels of total cholesterol. 57 People with high total
cholesterol have about twice the risk of heart disease as people with optimal levels. 57
Furthermore, certain conditions such as hypertension and diabetes can be exacerbated by
high levels of cholesterol in the blood.
The amount of people affected by cholesterol among the HIV population seems to
mirror the cholesterol levels among the general population. Low levels of HDL have been
reported among HIV patients, and are associated with hypertriglyceridemia (i.e. high
blood levels of triglycerides).5 33 34 Furthermore, low CD4 T-cell counts and high levels
of HIV-RNA viral load also are associated with low levels of HDL. 6 33 34 In 2006, El-
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Sadr et al. compared cholesterol levels among obese HIV patients and non-obese HIV
patients and determined that a higher BMI was associated with higher lipid levels.6 Some
research has suggested that the high levels of cholesterol in HIV patients is as a result of
the HIV medication.6 34 Additional research is needed to study the association between
cholesterol and HIV progression.
2.4b Hypertension
Blood pressure is the force of blood against your artery walls as it circulates
throughout your body.58 Blood pressure is measured using two numbers. The first number
is the systolic measurement and it represents the pressure in your blood vessels when
your heart beats. The second number is the diastolic measurement and it represents the
pressure in your vessels when your heart rests between beats. A normal blood pressure
reading is 120/80 mmHg, while someone with high blood pressure (hypertension) will
have a reading ≥ 140/90 mmHg. 58 Blood pressure tends to rise with age, but can be
controlled by following a healthy lifestyle. 58 Hypertension can lead to increased risk of
developing heart disease and stroke, which are the first and third leading causes of death
in the U.S. 50 About one out of every three adults (~31%) in the U.S. has hypertension.
Males, African Americans, and those of older age are more likely to develop
hypertension. 58
Among the HIV population, traditional risk factors are also associated with
hypertension.35 36 These factors include older age, overweight/obesity, family history of
hypertension, and increased levels of triglycerides. CD4 counts below 200 cells/mm3
show a tendency to be protective against hypertension in a univariate analysis, but this
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association was no longer seen when included in the full model.35 Most studies report that
the prevalence of hypertension among HIV patients is anywhere between 25%-35%,
which is very similar to the proportion of adults affected in the general population.35 36 37
38 39

Some studies have raised the possibility that HAART may induce hypertension

through hardening of the vessel walls,36 39 however others report minimal effects.37 38
2.4c Diabetes
Diabetes is a disease in which blood glucose levels are above normal.59 Your
body either does not make enough insulin or cannot use its own insulin as well as it
should, and can cause sugar build-up in the blood. Several risk factors are associated with
getting diabetes such as genetics, poor diet, overweight/obesity, and the environment.59
Tests such as the fasting blood glucose test, hemoglobin A1C, and oral glucose tolerance
test are all used to determine diagnosis of diabetes. 59 However, it does require that two
consecutive tests confirm this diagnosis.60 A fasting blood glucose test with values higher
than 126 mg/dL, a hemoglobin A1C test with values 6.5% or higher, and an oral glucose
tolerance test with values higher than 200 mg/dL all constitutes a positive diagnosis of
diabetes. 59 60 Risk factors for diabetes include older age, family history of diabetes,
physical inactivity, and race/ethnicity. 59 Diabetes can lead to heart disease, blindness,
kidney failure, and lower-extremity amputations. It is the seventh leading cause of death,
and affects more than 20 million Americans. 59
In HIV patients, mostly BMI, family history of diabetes, and certain HIV/AIDS
medications are associated with diagnosis of diabetes.40 41 The prevalence of diabetes
among HIV patients has been reported to be between 1%-10%.40 41 One study reported
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that incidence of diabetes increases with cumulative exposure to HAART.41 The HIV
population also tends to have a greater chance for the development of complications due
to diabetes when compared to HIV naïve patients.42 Certain opportunistic infections, such
as cytomegalovirus retinitis, can increase the chance of developing diabetic retinopathy in
HIV patients. 42 Therefore, it may be possible that control of such opportunistic infections
may help in reducing the diabetic complications seen in HIV patients.
2.5 Public Health Importance
Taken together, studying factors that influence progression of HIV is imperative.
Non-traditional factors such as BMI may be useful to clinicians in providing the best
clinical plan for each individual HIV patient. Furthermore, additional research on the risk
of cardiovascular disease in HIV patients is needed. The populations sampled in past
research have not provided the best population for studying this relationship. The
population that will be sampled for our study will offer an array of HIV patients that will
allow us to determine whether an association exists in the era of HAART.

19

CHAPTER 3
METHODS
3.1

Study design
The design of this study will be a retrospective cohort, determining how BMI

(exposure) is associated with markers of HIV progression and cardiovascular disease risk.
The marker for HIV progression includes CD4 T-cell count, while the markers of
cardiovascular disease risk include fasting blood glucose, HDL, LDL, SBP and DBP. The
inclusion criteria will be HIV positive individuals who are at least 18 years of age, with
BMI being measured within three months of HIV diagnosis, and those with at least 1
follow-up after BMI was recorded at diagnosis. They will be grouped by their BMI status
into the following four categories: underweight, normal, overweight and obese. Both the
values and the measurement dates of CD4 T-cells, HIV-RNA viral load, fasting blood
glucose, HDL, LDL, SBP and DBP will be collected.
3.2

Study Population
Setting: Medical records from the Ryan White HIV/AIDS Clinic in Columbia,

SC will be reviewed to collect data for this study. The Ryan White HIV/AIDS program is
a federally funded program that reaches more than 529,000 people a year in the United
States.35 It funds primary care and support services to low-income and underserved
individuals and families living with HIV disease. 35 In 2007, the Ryan White program
served 11,554 clients in South Carolina, with 100% of those clients being affected by
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HIV. The majority of the clients served in the Ryan White Clinic in South Carolina are
male (60%), African American (73%), and aged 25-44 (50.7%).35
Time Period: Since this study looks to determine the associations after HAART
was introduced in 1996, we will include individuals who were newly diagnosed between
January 1, 1997 and December 31, 2010, which is a total of 14 years.
3.3

Data Analysis

AIM 1: To determine the association between BMI at diagnosis and a marker of
disease progression (CD4 T cell count) over time.
In order to determine the association between baseline BMI and markers of HIV,
the following formula will be used to calculate BMI: (weight in lbs. * 703)/(height in
inches2). Descriptive analyses will be conducted. Statistical analyses will utilize
Pearson’s χ2, Fisher’s exact, or Kruskal-Wallis tests for categorical variables and t-test for
continuous variables. A change between two test results is considered significant if it is a
30% change in absolute CD4 count or 3 percentage point change in CD4 percentage. A
mixed regression analysis will be conducted to determine whether the mean values of the
marker of HIV progression (CD4 count) are different over-time between BMI categories,
after adjusting for the following confounding variables: race, gender, age, marital status,
smoking, alcohol use, drug use, insurance, case manager, education, mode of
transmission delayed entry into care, and HAART use. These variables were chosen due
to their association between both BMI and the HIV disease. Tukey’s multiple
comparisons test will be used to determine which BMI categories’ mean values, if any,
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are different from each other. A loess fitting will be used if the data appears to be nonlinear. Graphical comparisons will also be performed.
Table 3.1: Independent variables for AIM 1

Variables

Date

Levels

Categories

HIV seroconversion/diagnosis

Baseline

Date

Date

Race/Ethnicity

Baseline

4

White (ref)
Black
Hispanic
Other

Gender

Baseline

2

Male (ref)
Female

Age

Baseline

5

<20
21-29 (ref)
30-39
40-49
50-59
≥60

Marital Status

Baseline

4

Single (ref)
Married
Divorced
Widowed

Smoking Status

Baseline

2

No (ref)
Yes

Alcohol Use

Baseline

2
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No (ref)

Yes
Drug Use

Baseline

2

No (ref)
Yes

Insurance

Baseline

5

Medicare
Medicaid
Private
Insurance
Other
None

Case Manager

Baseline

2

No (ref)
Yes

Education

Baseline

4

High School
diploma (ref)
Some college
College degree
Graduate
degree

Mode of Transmission

Baseline

4

Heterosexual
(ref)
MSM
IDU
NIR/NRR

Delayed entry into Care

Baseline

2

< 3 months
(ref)
≥ 3 months

Weight

Baseline

Continuous
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Continuous

Height

Baseline

ART/HAART use

Continuous

Continuous

2

No (ref)
Yes

CD4 count

Baseline

Continuous

Continuous

CD4 count (outcome)

Overtime1

Continuous

Continuous

HIV-RNA viral load

Baseline

Continuous

Continuous

1The date that each variable is measured, after diagnosis of HIV, will be recorded as well.

AIM 2: To determine whether the association between BMI at diagnosis and a
marker of disease progression (CD4 T cell count) over time differ by gender.
To determine whether AIM 1 varies by race and sex, investigators will use the
same variables that will be used to analyze AIM 1, but will stratify the results by the
gender (Male and Female). The following formula will be used to calculate BMI:
(weight in lbs. * 703)/(height in inches2). Gender differences in demographic and clinical
characteristics will be assessed by using Pearson’s χ2 , Fisher’s exact, or Kruskal-Wallis
tests for categorical variables and t-test for continuous variables. A change between two
test results is considered significant if it is a 30% change in absolute CD4 count or 3
percentage point change in CD4 percentage. A mixed regression analysis will be
conducted to determine whether the mean values of the marker of HIV progression (CD4
count) are different over-time between BMI categories vary by gender, after adjusting for
the following confounding variables: age, race, marital status, smoking, alcohol use,
drug use, insurance, case manager, education, mode of transmission, delayed entry into
care and HAART use. Tukey’s multiple comparisons test will be used to determine which
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BMI categories’ mean values, if any, are different from each other. A loess fitting will be
used if the data appears to be non-linear. Graphical comparisons will also be performed.
Table 3.2: Independent variables for AIM 2

Variables

Date

Levels

Categories

HIV seroconversion/diagnosis

Baseline

Date

Date

Race/Ethnicity

Baseline

4

White
Black
Hispanic
Other

Gender

Baseline

2

Male
Female

Age

Baseline

5

<20
21-29 (ref)
30-39
40-49
50-59
≥60

Marital Status

Baseline

4

Single (ref)
Married
Divorced
Widowed

Smoking Status

Baseline

2

No (ref)
Yes

Alcohol Use

Baseline

2
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No (ref)

Yes
Drug Use

Baseline

2

No (ref)
Yes

Insurance

Baseline

5

Medicare
Medicaid
Private
Insurance
Other
None

Case Manager

Baseline

2

No (ref)
Yes

Education

Baseline

4

High School
diploma (ref)
Some college
College degree
Graduate
degree

Mode of Transmission

Baseline

4

Heterosexual
(ref)
MSM
IDU
NIR/NRR

Delayed entry into Care

Baseline

2

< 3 months
(ref)
≥ 3 months

Weight

Baseline

Continuous
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Continuous

Height

Baseline

ART/HAART use

Continuous

Continuous

2

No (ref)
Yes

CD4 count

Baseline

Continuous

Continuous

CD4 count

Overtime1

Continuous

Continuous

HIV-RNA viral load

Baseline

Continuous

Continuous

1The date that each variable is measured, after diagnosis of HIV, will be recorded as well.

AIM 3: To determine the association between BMI at diagnosis and markers of
cardiovascular disease risk (Fasting blood glucose, HDL and LDL, and SBP and
DBP) over time.
In order to determine the association between baseline BMI and markers of HIV,
the following formula will be used to calculate BMI: (weight in lbs. * 703)/(height in
inches2). Descriptive analyses will be conducted as well. Statistical analyses will
Pearson’s χ2, Fisher’s exact, or Kruskal-Wallis tests for categorical variables and t-test for
continuous variables. A mixed regression analysis will be conducted to determine
whether the mean values of the markers of cardiovascular disease risk are different overtime between BMI categories, after adjusting for the following confounding variables:
race, gender, age, marital status, smoking, alcohol use, drug use, insurance, case
manager, education, mode of transmission, delayed entry into care, baseline CD4 count,
baseline VL, baseline fasting blood glucose, baseline HDL, baseline LDL, baseline SBP
and DBP, and HAART use. These variables were chosen due to their association between
both BMI and the HIV disease. Tukey’s multiple comparisons test will be used to
determine which BMI categories’ mean values, if any, are different from each other. A
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loess fitting will be used if the data appears to be non-linear. Graphical comparisons will
also be performed.
Those on cholesterol, hypertension and diabetic medications before diagnosis will
be excluded from the analysis.
Table 3.3: Independent variables for AIM 3

Variables

Date

Levels

Categories

HIV seroconversion/diagnosis

Baseline

Date

Date

Race/Ethnicity

Baseline

4

White (ref)
Black
Hispanic
Other

Gender

Baseline

2

Male (ref)
Female

Age

Baseline

5

<20
21-29 (ref)
30-39
40-49
50-59
≥60

Marital Status

Baseline

4

Single (ref)
Married
Divorced
Widowed
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Smoking Status

Baseline

2

No (ref)
Yes

Alcohol Use

Baseline

2

No (ref)
Yes

Drug Use

Baseline

2

No (ref)
Yes

Insurance

Baseline

5

Medicare
Medicaid
Private
Insurance
Other
None

Case Manager

Baseline

2

No (ref)
Yes

Education

Baseline

4

High School
diploma (ref)
Some college
College degree
Graduate
degree

Mode of Transmission

Baseline

4

Heterosexual
(ref)
MSM
IDU

Weight

Baseline

Continuous
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Continuous

Height

Baseline

ART/HAART use

Continuous

Continuous

2

No (ref)
Yes

HDL and LDL

Baseline

Continuous

Continuous

Blood Pressure (Systolic and
Diastolic)

Baseline

Continuous

Continuous

Fasting blood glucose

Baseline

Continuous

Continuous

HDL and LDL

Overtime1

Continuous

Continuous

Blood Pressure (Systolic and
Diastolic)

Overtime1

2

Continuous

Blood Glucose Levels
(fasting)

Overtime1

2

Continuous

1The date that each variable is measured, after diagnosis of HIV, will be recorded as well.

Data management and statistical analyses will be performed using SAS 9.2
software. Proc mixed will be used to perform the mixed model analyses.
Sample Size/Power Analysis
A power analysis was conducted using SAS Proc Power to determine sample size
needed for each BMI category. Since each AIM will be analyzed using a mixed model
analysis, mean values of CD4 count were used (Table 4). Compared to the other
outcomes that will be analyzed in this dissertation, CD4 was also used since it had the
largest standard deviation, which causes the sample size to be larger compared to smaller
standard deviations. These numbers were averaged from previous studies reports of mean
CD4 counts for each BMI category.17 22 23 24 25 An average from these studies were
calculated and used in the power analysis. Alpha was set to 0.05 and power was set to
0.80.
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Table 3.4: Power Analysis: Average CD4 counts per BMI category

BMI Category

Average CD4 count

Underweight

346

Normal

412

Overweight

451

Obese

473

The power analysis determined that at least 85 HIV patients are needed in each
group to ensure an 80% power for the study. We also determined how sample size affects
power by computing sample size needed per group at different powers (Table 5)
Table 3.5: Power Analysis: Number (N) of HIV patients per BMI category needed at different
powers

N Per Group

Power

5

0.082

10

0.127

15

0.176

20

0.228

25

0.282

30

0.336

35

0.390

40

0.442

45

0.492
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50

0.541

55

0.586

60

0.629

65

0.668

70

0.705

75

0.738

80

0.769

85

0.796

90

0.821

95

0.843

100

0.863

105

0.881

110

0.897

115

0.911

120

0.923

125

0.933

130

0.943

135

0.951

140

0.958

145

0.964

150

0.969
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Protection Measures
All study personnel will be trained and certified in federal and state policies
regarding the protection of human subjects’ participation in research. The human subjects
data used in AIMS 1, 2, and 3 of this proposal are part of the University of South
Carolina’s Ryan White Clinic program. Careful consideration will be taken to ensure the
anonymity of study participants. No individual will be identified in any publications
resulting from this study. To further protect patient confidentiality, the researcher will
have access to the medical records and will be required to sign a confidentiality
agreement and attend a USC sponsored Health Insurance Portability and Accountability
Act (HIPPA) training. The data will be abstracted from the medical records on forms that
will not contain any identifying information. The abstracted data will be entered into an
electronic database which will be used in the analysis. This investigation will pose only
a minimal risk to the privacy of individuals, and the proposed research falls under
Exemption 4 (AIM 1, AIM 2, and AIM 3) and Expedited Review Category 5 (AIM 1,
AIM 2, and AIM 3). An application will be submitted to the University of South Carolina
Institutional Review Board to approve this study (Please see Appendix A for a more
detailed description of the Human Subjects Protection).
Strengths and Limitations
There is a strong need for simple and affordable clinical criteria (i.e. BMI) to
guide interventions such as the initiation of treatment and monitor progression of HIV.
This is of particular importance in resource-limited countries such as the sub-Saharan
Africa, where tests to measure CD4 and HIV-RNA viral load may not be available due to
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expenses. Ultimately, the use of BMI could aid in reducing the onset of morbidity and
mortality.
Most of the studies that have investigated this relationship have studied BMI as a
time-dependent variable. There are limited studies that have looked at the effect of BMI
at diagnosis as a marker to determine disease progression. However, this proposal will
determine its association with both disease progression and cardiovascular risk due to the
recent evidence in this field of research.
A limitation to this proposal is that there is potential for missing data (CD4 cell
count, HIV-RNA viral load, HDL, LDL, TG), but it is anticipated to be minimal.
Summary
This proposal outlined is significant because it looks to determine whether the use
of BMI could be a basic prognostic factor used to measure HIV progression. Also, there
is needed research in the field of nutrition and HIV to determine its relation as HIV
continues to become more of a chronic disease. Dissertation committee chair, Dr. Anwar
Merchant, has experience epidemiology, nutrition, and HIV research. Dr. Bo Cai,
committee member, has experience in biostatistics. Dr. Kellee White, committee
member, has experience in cardiovascular epidemiology. Dr. Wayne Duffus, committee
member, has experience in HIV research. Combined, these investigators have an
extensive background conducting epidemiological research and possess the
methodological skills needed to successfully complete this study.
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CHAPTER 4
LONGITUDINAL ASSOCIATION BETWEEN BODY MASS INDEX (BMI) AT
DIAGNOSIS AND HIV DISEASE PROGRESSION
4.1 Introduction
Malnutrition and an underweight appearance were characteristics formerly
associated with HIV/AIDS infection and were predictive of increased mortality.21
However, since the introduction of Highly Active Antiretroviral Therapy (HAART) in
1996, mortality has decreased, the progression of HIV to AIDS has decelerated, and
HAART treated individuals are experiencing weight gain and becoming more overweight
(Body Mass Index (BMI): 25 – 29.9 kg/m2) and obese (BMI: ≥ 30 kg/m2).7 Some
studies report that the obesity prevalence among the HIV population is now beginning to
mirror the obesity epidemic among the general population.7 21
Pre-HAART research evaluating the association between BMI and HIV
progression has shown either no association20 22 or that HIV-infected individuals with
higher BMI levels are less likely to progress to AIDS and die as compared to those with
normal weight individuals (BMI: ≤ 24.9 kg/m2).17 24 60 However, in the post-HAART era,
the different increased BMI categories (overweight and obese) may be differentially
associated with disease progression and survival. For example, overweight individuals
are reported to have a slower progression to AIDS compared to those who were obese.25
However, obese HIV-infected individuals on HAART are reported to experience smaller
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increases in CD4-positive T-lymphocyte count (CD4), implying that obesity may actually
be harmful.26 27 These data suggest, that although HAART is associated with
improvements in morbidity and mortality, progressive weight gain may additionally
influence immune recovery, which may be reversed or slowed. However, there is a
paucity of studies examining this relationship in the post HAART era.
This study is important because it was conducted in the southern United States, a
region that suffers from one of the highest burdens of HIV-infected individuals,1 and
overweight and obese individuals.19 Whereas previous studies have focused on mortality,
this study investigates the longitudinal association of BMI at HIV diagnosis with disease
progression as evaluated by CD4 counts obtained during routine medical care.
4.2 Methods
This is a cohort study of individuals who were receiving care at the Ryan White Clinic in
Columbia, SC. Participants were eligible if they were diagnosed with HIV-infection from
January 1, 1997 through December 31, 2010, were at least 18 years of age, had weight
and height measurements within three months of HIV diagnosis, were HAART-naïve,
and had at least one follow-up visit (within six months) after entering into care.
Individuals who were pregnant when diagnosed and those diagnosed with AIDS at the
initial visit were excluded. This study was approved by the University of South Carolina
Institutional Review Board.
The power analysis, using the difference between mean CD4 counts by BMI
category from past research, determined that at least 85 HIV-infected individuals are
needed in each group to ensure an 80% power for the study. Investigators abstracted deidentified data from 409 medical records. However, since there were only 13 underweight
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(BMI: <18.5 kg/m2) HIV-infected individuals, this category was excluded from the
analyses. A total of 396 individuals were included in the final analyses.
Variables
Outcome: The outcome evaluated for this study was CD4 cell count (cells/mm3)
assessed over the course of medical care follow-up. CD4 cell count was used to stage
disease and is monitored routinely by providers to determine when to start HAART and
to assess response to treatment. CD4 cell count was used as a continuous variable in the
analysis.
Exposure: Body mass index at diagnosis was the main exposure variable. This
was estimated by dividing weight in kg by height (measured at diagnosis) in m2 measured
within three months after diagnosis. BMI was grouped into three categories: normal (<25
kg/m2), overweight (25-29.5 kg/m2 ), and obese (≥30 kg/m2).
Time varying covariates: HIV viral load (VL) (copies/mL) was collected at
diagnosis and monitored over the course of follow-up to assess ongoing response to
treatment. HAART use was defined as any prescription for HIV medication over the
course of medical care. All data was extracted from the participants’ medical records.
Other variables recorded at baseline include age, gender, race/ethnicity, marital
status, education, type of insurance, use of case management, alcohol use, smoking
status, drug use, mode of transmission, and delayed entry into care (defined later). Age
was grouped into the following five categories when included in the multivariate
analysis: < 20; 20-29; 30-39; 40-49; 50-59; and > 60. The following categories were
used for race/ethnicity: White, non-Hispanic; Black, non-Hispanic; Hispanic; Other; and
Unknown. Education was grouped into these categories: no high school diploma, high
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school diploma, associate degree, bachelor degree, master’s degree, or doctoral degree.
Type of insurance was based on primary insurance and was clustered into these
categories: Medicare; Medicaid; Private Insurance or none (includes individuals enrolled
in the AIDS Drug Assistance Program). Mode of transmission was grouped into four
categories: heterosexual, men who have sex with men (MSM), injection drug users, or
no identified risk/no reported risk (NIR/NRR). Given that timely linkage to care has the
potential to improve health outcomes and prevent secondary HIV transmission,61 the
delayed entry into care variable was used as a covariate to adjust for differences between
those who seek care early versus those who do not. Delayed entry into care was
determined by subtracting the date of diagnosis from the date of first visit to the clinic,
and was grouped into the two categories: ≤3 months and ˃3 months.62 When an
individual is diagnosed with HIV at the Ryan White Clinic, he or she is offered the
services of a case manager to help the individual access care and other support services.
Case management was defined as present if the individual had an assigned case manager
and absent otherwise. We adjusted for this variable because there may be a difference in
clinical care outcome associated with case management status. Current alcohol use,
current smoking status, and current drug use were all assessed by yes or no questions.
Visit number was entered into the analysis to control for time in study. Therefore, the
first visit represented time point one, the second visit represented time point two, and so
forth.
Statistical Analyses
Demographic and clinical characteristics of the participants were compared across
the three BMI categories, using means and standard error (SE) for continuous variables

38

and number (n) and percent (%) for categorical variables. Differences in clinical
characteristics were compared using F-test for continuous variables and Pearson χ2,
Fisher’s exact, or Kruskal-Wallis tests for categorical variables as appropriate.
To determine the association between BMI at diagnosis and longitudinal CD4 cell
counts, data were analyzed using mixed regression models. Age group, race/ethnicity,
gender, use of case management, marital status, education, insurance type, delayed entry
into care, mode of transmission, alcohol use, smoking status, drug use, CD4 count at
diagnosis, and HIV VL at diagnosis and overtime were all adjusted for in the analysis
given their relationship to BMI or HIV progression. Variables were included into the
model sequentially: Model 1: BMI group, age group, race/ethnicity, gender, HAART
use, baseline CD4 count, baseline HIV VL, HIV VL over time, and mode of
transmission; Model 2: Model 1 + alcohol use, smoking status, and drug use; Model 3:
Model 2 + marital status, education, and insurance type; Model 4: Model 3 + use of case
management; Model 5: Model 4 + delayed entry into care. The mixed model analysis
was also stratified by baseline VL and delayed entry into care. For this analysis, baseline
VL was grouped into ≤100,000 copies/mL plasma and ˃100,000 copies/mL plasma.
Adjusted CD4 count means were determined and graphed at five different time points by
using an lsmeans statement in the mixed regression model, with tukey option to
determine differences between BMI categories. The five time points were determined
from quantiles obtained from a univariate analysis. Sensitivity analyses were conducted
to test whether loss to follow-up (i.e. those with > 6 months after the last documented
visit) impacted the results and the data were re-analyzed using the inverse-probability
weighting method as suggested by Hernan.63 Statistical analyses were performed using
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SAS 9.2 (SAS Institute; Cary, North Carolina). For all analyses, the α-level was set at
0.05.
4.3 Results
Baseline Characteristics
The overall study population’s mean baseline BMI was 27.4 kg/m2 (overweight)
and mean age was 35 years. The study population were predominantly male (61.9%),
black (74.2%), and single (61.1%); approximately 35.3% had at least a high school
diploma,47.2% did not have insurance, 57.1% were not followed by a case manager,
60.9% used alcohol, 54.8% smoked, 59.8% did not report drug use, 55.8% were
heterosexual, 56.8% entered care > 3 months of diagnosis, and 88.1% were prescribed
HAART during course of medical care (Table 1).
BMI categories were not related to age, race/ethnicity, marital status, educational
attainment, type of insurance, use of case manager, and HAART use. However, gender,
alcohol use, smoking status, drug use, mode of transmission, delayed entry into care,
CD4 count at diagnosis, and HIV VL at diagnosis were all significantly different among
the BMI categories. Obese HIV-infected individuals were more likely to be female
(60.4%), non-alcohol users at diagnosis (44.3%), to non-smokers (53.8%), and had the
lowest HIV VL at baseline (4.5 logs), and the highest CD4 count at baseline (575.6
cells/mm3) compared to the normal and overweight weight individuals.
BMI and CD4 count over time
The overall mean follow-up time was 6.7 years and was similar across the BMI
categories (P=0.108). The overall mean CD4 count over time was 579.3 cells/mm3 . Mean
CD4 count was highest among obese individuals (611.2 cells/mm3), followed by
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overweight individuals (598.1 cells/mm3 ) and normal weight individuals (550.5
cells/mm3).
Mixed models were used to determine whether CD4 count change over time was
different among BMI categories (Table 2). After adjusting for the variables listed in
Table 1, there were significant differences in mean CD4 count for the overweight and
obese categories when compared to the normal weight category. Models 1 thru 5 (full
model) were all determined to be significant. Compared with the normal weight
individuals in the full model, the obese category had significantly larger increases in CD4
count (5.5 cells/mm3, P = <0.001) versus the decrease in CD4 count in the overweight
category (-2.1 cells/mm3, P = <0.001). For an example, after visit one, it is predicted that
obese HIV-infected individuals at diagnosis will experience a 5.5 cells/mm3 increase in
CD4 count, while obese HIV-infected individuals will experience a 2.1 decrease in CD4
count. The results of the sensitivity analyses using the inverse-probability weighting
method to account for loss to follow up (n=73) were qualitatively similar to the results
presented.
Overall, mean CD4 count increased over time. Figure 1 shows a significant
interaction between BMI and CD4 count using the adjusted mean CD4 counts. While the
adjusted mean CD4 count was higher at the outset for the overweight and normal weight
groups compared to the obese category, over time the CD4 count trend increased among
the obese and normal weight categories and decreased for the overweight category
(Figure 1). Figure 2 displays the differences in adjusted mean CD4 counts when
compared to the normal weight group. The overweight category had the greatest
difference in adjusted mean CD4 counts when compared to the normal weight group. The
41

adjusted mean CD4 counts at visit one, visit forty-two, and visit fifty-four among the
overweight category were statistically different from the normal weight group’s adjusted
means.
The interaction between BMI and time among those with lower baseline VL
values (<100,000 copies/mL plasma) were significant for the overweight and obese
categories when compared to the normal weight individuals (time*overweight P <0.001,
time*obese P <0.001) (Table 3). Significantly larger increases in CD4 count were seen in
the obese category (3.3 cells/mm3) versus the overweight category who experienced
decreases in CD4 count (-1.8 cells/mm3 ). Among those with higher baseline VL values
(>100,000 copies/mL plasma), the interaction between BMI at time were significant for
the overweight and obese categories when compared to normal weight individuals
(time*overweight P <0.001, time*obese P <0.001). Significant decreases in CD4 count
were seen in the obese category (-2.1 cells/mm3) and the overweight category (-1.6
cells/mm3).
For those individuals who entered care within three months of diagnosis, the
interaction between BMI and time were significant when compared to the normal
weight patients (time*overweight P <0.001, time*obese P <0.001) (Table 3).
Significantly larger increases in CD4 count were seen in the obese category (9.4
cells/mm3) versus the overweight category that experienced decreases in CD4 count (-2.9
cells/mm3). In those who received care after three months of diagnosis, the interactions
between BMI and time were significant (time*overweight P <0.001, time*obese P
<0.001) when compared to the normal weight category, with the obese category
experiencing increases in CD4 count (2.6 cells/mm3) and the overweight category (-1.4
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cells/mm3) experiencing decreases in CD4 cell count when compared to the normal
weight category.
4.4 Discussion
Within this cohort of HIV-infected individuals, CD4 counts were highest at time
of diagnosis among those who were obese compared to those in the overweight and
normal weight categories. CD4 counts at diagnosis also were higher for individuals who
entered care within three months of diagnosis and those who had lower baseline VL
values (<100,000 copies/mL). Over time CD4 count increases were highest for the obese
followed by the normal weight groups, but decreased for the overweight category after
adjusting for potential confounders. Although very high BMI among HIV-infected
individuals is associated with increased CD4 count over time, moderately high BMI was
not. Although our results are different from recent post-HAART studies that have
evaluated this relationship, it suggests that obesity may still be beneficial to the immune
recovery gained from HAART.
During the pre-HAART (before 1996) era, several studies reported that obese
HIV-infected individuals had better survival over time.17 22 Van der Sande et al.
discovered that the median survival time of those presenting with BMI < 16 was
significantly lower than the median survival time for those with a baseline BMI ≥ 22.17
In the current investigation, we were unable to study those with BMI < 18.5 due to an
insufficient number of underweight individuals. Shor-Posner et al. found that while CD4
cell count over time was higher for obese individuals compared with the non-obese group
(376 cells/mm3 vs. 364 cells/mm3), the difference was not statistically significant.22
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A few studies found that overweight individuals have larger increases in CD4
counts over time during the pre-HAART era.24 60Jones et al. reported a significant
difference in CD4 count among BMI categories, with the overweight group experiencing
larger increases in CD4 counts, followed by those of normal weight and underweight.24
With survival as the outcome, Shuter et al. found that overweight individuals progressed
more slowly to AIDS, and CD4 count was not independently predictive of progression to
AIDS. 60
Whereas the results by Van der Sande et al. and Shor-Posner et al. are similar to
our findings, these studies were conducted during the pre-HAART era and their
population consisted of only women24 or had a limited sample size.60 Koethe et al.
recently investigated the relationship between BMI and HIV progression by following
HIV-infected adults starting treatment between 1998 and 2008 (post-HAART era) and
discovered that overweight HIV-infected individuals experienced a 12-month CD4 count
gain in women (+ 9 cells/ uL), but not in men (-1 cells/uL), while the normal weight (-65
cells/uL) and obese categories (-12 cells/uL) experienced a reduction.25 They suggested
that there may be an optimal BMI range for immune recovery once on treatment for a
year, with immune reconstitution reaching a plateau in the range of BMI 25 to 30 kg/m2.
Crum-Cianflone et al. reported that in the HAART era, obese HIV-infected individuals
had smaller increases in CD4 counts (+69 cells/mm3) compared to those in the
overweight (+116 cells/mm3) and normal weight categories (+102 cells/mm3 ).26 Although
previous post-HAART studies report different results, our results could be due to our
study population being from South Carolina where high levels of HIV and obesity exist.
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There are a few proposed clinical explanations for our results. First, leptin is a
satiety hormone that circulates directly proportional to weight and is known to increase
with inflammation.64 Obese individuals have a higher concentration of leptin compared to
overweight and normal weight individuals and given HIV causes inflammation and CD4
cells have leptin receptors and has a proliferation effect, it could explain the increase or
higher levels of CD4 among obese individuals. Secondly, obesity is surplus of energy in
the form of stored fat that acts to spare protein from being used as an energy source,
which aids in preserving immune function.19 This helps to neutralize the high metabolic
rate of HIV and could explain the protective effect of obesity on CD4 levels. Thirdly, as
Jones et al proposed, since untreated HIV-infection is associated with weight loss,
individuals in the normal weight category are a mixed group consisting of both
individuals who were normal weight pre-diagnosis, and those who were overweight but
lost weight because of HIV-infection in the period preceding their diagnosis.24
Furthermore, individuals in the overweight category are a mixed group consisting of both
individuals who were overweight pre-diagnosis, and those who were obese but lost
weight because of HIV-infection. These explanations are an example of reverse causality
and a potential confounder in all studies evaluating this question.
To prevent the possibility of weight change being mis-classified into another BMI
category, height and weight was collected within three months of diagnosis. If reverse
causality is contributing to the association between BMI and HIV progression, then the
BMI characteristics of the source population are likely important. As HIV is diagnosed at
an earlier stage, before wasting sets in, the HIV-infected population is similar to the
general population with respect to BMI. In our study population the mean BMI was 27.4
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kg/m2, and overweight and obesity prevalence was 30% and 26.8%, which is similar to
the prevalence of overweight (35.4%) and obesity (31.5%) in general HIV-uninfected
population in South Carolina.19 However, the percentages differ the population of HIVinfected drug users in the report by Shor-Posner et al. (overweight or obese 18%),4 or
HIV-infected predominantly Latino population attending an urban health clinic in Bronx,
NY in the report by Shuter et al. (overweight 21.7%),60 or high risk women (history of
injection drug use or high-risk sexual contact) in the report by Jones et al.(obesity
18.8%).24 The characteristics of the study population in this report were similar for all
HIV-infected individuals in the entire state of South Carolina, with respect to race (Black:
74.2% versus 76%) and mode of transmission (MSM: 33.1% versus 37.1%).66 Given the
similarities between our study cohort and the overall HIV-infected population in South
Carolina, it is unlikely that reverse causality significantly impacted our results.
There are several limitations to our study. First, the secular change of CD4 count
is impacted as more HIV-infected individuals are prescribed HAART and medication
efficacy has increased, which could potentially attenuate the associations.67 Second, our
population consisted of mostly black HIV-infected individuals and the results may not be
generalizable to other populations. Third, we were unable to make an assumption that
included the underweight BMI category. However, past research has shown that
underweight individuals generally have a faster progression to AIDS and death compared
to other BMI categories.17 24 25 Fourth, the treatment variable only measured whether
individuals received HAART throughout the course of their HIV infection. We did not
assess time spent on HAART. Fifth, there is the possibility of residual confounding.
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Finally, the alcohol use and drug use variables only captured whether individuals were
socially participating in these factors and not the frequency of use.
Our study has several strengths. First, we investigated the post-HAART
longitudinal association between BMI at baseline and HIV progression in a southern
state. In contrast, the majority of other studies from other regions focused on survival
rather than continuous immune function. Second, unlike previous research, we adjusted
for many potential confounders including delayed entry into HIV medical care and use of
case management. Entry into HIV medical care is essential for access to antiretroviral
therapy and facilitates the delivery of important prevention education to reduce HIV
transmission. In addition, retention in care is necessary to monitor response to therapy.
Therefore, adjusting for delayed entry into care is important to accurately determine the
association between BMI and HIV progression as it relates to both. Whereas our results
were similar to Koethe’s et al. results in regards to mean CD4 counts, they were not able
to adjust for educational attainment or insurance type.25 The current study was able to
gain an improved estimation of the relationship between BMI at diagnosis and CD4 count
over time by adjusting for these variables. Third, our population of individuals with
different stages of HIV disease, allows us to determine if the relationship under study
exists in HIV-infected individuals with different levels of immune impairment. Fourth,
the inverse probability weighting method used to evaluate the possible impact of loss to
follow-up provided materially similar results to those reported. Finally, this investigation
includes fourteen years of follow-up (i.e. those diagnosed in 1997) allowing us to assess
CD4 count over a long period.
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Our study results demonstrate that HIV-infected individuals who were obese at
diagnosis had greater increases in CD4 counts over time when compared to HIV-infected
individuals who were overweight and normal weight at diagnosis. This suggests that
providers should pay closer attention to weight at diagnosis to predict the response to
treatment. Additional studies are needed among different populations to support the
conflicting results produced by studies that have evaluated this relationship. Because
BMI at diagnosis may be an important factor in predicting disease trajectory in the postHAART era, other studies are needed to evaluate immune impairment of those with high
BMI and establish a biologic basis for the observed differences.
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Table 4.1: Baseline characteristics of South Carolina HIV-infected individals diagnosed between
1997 and 2010 by Body Mass Index (BMI) category.
Characteristic
Overall
Normal
Overweight
Obese
Pa
(n=396)
(n=171)
(n=119)
(n=106)
Body Mass Index
27.4 ± 6.3
22.3 ± 1.8
27.2 ± 1.5
35.9 ± 5.2
<0.001
Age
35.1 ± 10.6
34.5 ± 11.5
36.1 ± 9.5
34.5 ± 10.2
0.378
Gender
Male
245 (61.9%)
126 (73.7%)
78 (65.6%)
41 (38.7%)
Female
149 (37.6%)
44 (25.7%)
41 (34.5%)
64 (60.4%)
Transgender
2 (0.5%)
1 (0.6%)
1 (0.9%)
<0.001
Race
White, non-Hispanic
92 (23.2%)
38 (22.2%)
28 (23.6%)
26 (24.5%)
Black, non-Hispanic
294 (74.2%)
127 (74.3%)
88 (74.0%)
79 (74.5%)
Hispanic
3 (0.8%)
2 (1.2%)
1 (0.8%)
Other
1 (0.3%)
1 (0.8%)
Unknown
6 (1.5%)
4 (2.3%)
1 (0.8%)
1 (1.0%)
0.899
Marital Status
Single
242 (61.1%)
111 (64.9%)
71 (59.7%)
60 (56.6%)
Married
47 (11.9%)
15 (8.8%)
19 (16.0%)
13 (12.3%)
Divorced
70 (17.7%)
25 (14.6%)
18 (15.1%)
27 (25.5%)
Widowed
14 (3.5%)
7 (4.1%)
5 (4.2%)
2 (1.9%)
Partnered
21 (5.3%)
12 (7.0%)
6 (5.0%)
3 (2.8%)
Unknown
2 (0.5%)
1 (0.6%)
1 (0.9%)
0.166
Education
No HS Diploma
63 (35.3%)
34 (19.9%)
13 (10.9%)
16 (15.1%)
High School Diploma
140 (5.8%)
61 (35.6%)
45 (37.8%)
34 (32.1%)
Associate Degree
23 (6.1%)
8 (4.7%)
4 (3.4%)
11 (10.4%)
Bachelor Degree
24 (2.3%)
6 (3.5%)
8 (6.7%)
10 (9.4%)
Master’s Degree
9 (0.8%)
4 (2.3%)
3 (2.6%)
2 (1.9%)
Doctorate Degree
3 (15.9%)
2 (1.2%)
1 (0.8%)
Unknown
134 (33.8%)
56 (32.8%)
45 (37.8%)
33 (31.1%)
<0.001
Insurance
Medicare
70 (17.7%)
33 (19.3%)
19 (16.0%)
18 (17.0%)
Medicaid
43 (10.9%)
17 (9.9%)
10 (8.4%)
16 (15.1%)
Private Insurance
96 (24.2%)
30 (17.6%)
35 (29.4%)
31 (29.3%)
None
187 (47.2%)
91 (53.2%)
55 (46.2%)
41 (38.7%)
0.064
Followed by Case Manager
Yes
170 (42.9%)
82 (47.9%)
44 (37.0%)
44 (41.5%)
No
226 (57.1%)
89 (52.1%)
75 (63.0%)
62 (58.5%)
0.170
Alcohol Use
Yes
241 (60.9%)
117 (68.4%)
73 (61.3%)
51 (48.1%)
No
138 (34.8%)
49 (28.7%)
42 (35.3%)
47 (44.3%)
Unknown
17 (4.3%)
5 (2.9%)
4 (3.4%)
8 (7.6%)
0.017
Smoking
Yes
217 (54.8%)
114 (66.7%)
63 (53.0%)
40 (37.7%)
No
162 (40.9%)
52 (30.4%)
53 (44.5%)
57 (53.8%)
Unknown
17 (4.3%)
5 (2.9%)
3 (2.5%)
9 (8.5%)
<0.001
Drug Use
Yes
141 (35.6%)
72 (42.1%)
44 (37.0%)
25 (23.6%)
No
237 (59.8%)
94 (55.0%)
71 (59.7%)
72 (67.9%)
Unknown
17 (4.6%)
5 (2.9%)
4 (3.3%)
9 (8.5%)
0.010
Delayed entry into care
<3 months
171 (43.2%)
78 (45.6%)
39 (32.8%)
54 (50.9%)
≥3 months
225 (56.8%)
93 (54.4%)
80 (67.2%)
52 (49.1%)
0.016
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HAART use
Yes
No
CD4 count at diagnosis

365 (88.1%)
31 (11.9%)
499.3 ± 255.2

161 (94.2%)
10 (5.8%)
448.4 ± 229.1

109 (91.6%)
10 (8.4%)
498.4 ± 231.1

95 (89.6%)
11 (10.4%)
575.6 ± 296.2

0.109
0.019

Log HIV VL at diagnosis
4.1 ± 0.9
4.2 ± 0.9
4.2 ± 0.9
3.8 ± 0.9
<0.001
Abbreviations: MSM, men who have sex with men; IDU, injecting drug user; NIR/NRR, no
identified/reported risk factor
NOTE: Mean and standard deviation are shown for Body mass Index, Age, CD4 count at diagnosis, HIV
VL at diagnosis.
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2). Underweight individuals
were excluded because numbers were too few for meaningful analysis.
a
Comparison between baseline BMI strata
**Insurance – None: No insurance/ADAP Program
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Table 4.2: Mixed Model Analysis of the association between Body
Mass Index (BMI) and CD4 count among HIV-infected individuals
diagnosed in South Carolina between 1997 and 2010.
Model
Parameter
Standard
Pb
Estimate
Error (SE)
Model 1
Time
4.9
0.002
<0.001
BMI
Obese
20.8
0.07
<0.001
Overweight
124.2
0.07
<0.001
Normal
*
*
*
BMI*time
time*Obese
0.8
0.004
<0.001
time*Overweight
-7.3
0.004
<0.001
time*Normal
*
*
*
Model 2
Time
4.9
0.003
<0.001
BMI
Obese
6.2
0.07
<0.001
Overweight
120.8
0.07
<0.001
Normal
*
*
*
BMI*time
time*Obese
0.8
0.004
<0.001
time*Overweight
-7.5
0.004
<0.001
time*Normal
*
*
*
Model 3
Time
4.9
0.003
<0.001
BMI
Obese
-7.5
0.08
<0.001
Overweight
107.8
0.07
<0.001
Normal
*
*
BMI*time
*
time*Obese
0.5
0.005
<0.001
time*Overweight
-7.2
0.005
<0.001
time*Normal
*
*
*
Model 4
Time
5.0
0.003
<0.001
BMI
Obese
-14.5
0.08
<0.001
Overweight
101.8
0.07
<0.001
Normal
*
*
*
BMI*time
time*Obese
0.6
0.005
<0.001
time*Overweight
-7.2
0.004
<0.001
time*Normal
*
*
Model 5 (Full model)
Time
5.1
0.003
<0.001
BMI
Obese
-13.3
0.08
<0.001
Overweight
106.7
0.07
<0.001
Normal
*
*
*
BMI*time
time*Obese
0.4
0.005
<0.001
time*Overweight
-7.2
0.004
<0.001
time*Normal
*
*
*
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Abbreviations: SE, standard error
NOTE: * Normal BMI category - reference group. The parameter estimates
represent the difference in the adjusted mean CD4 count by BMI category. Those
overweight has higher mean CD4 counts. b Comparison between baseline BMI
categories.
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2)
- Underweight individuals were excluded because numbers were too few for
meaningful analysis.
- Model 1 includes BMI, baseline CD4 count, baseline VL, viral load over time,
age, gender, race, mode of transmission and treatment.
- Model 2 includes Model 1 + alcohol, smoking, and drug use.
- Model 3 includes Model 2 + marital status, education, and type of insurance
- Model 4 includes Model 3 + case management
- Model 5 includes Model 4 + delayed entry into care

Table 4.3: Mixed Model Analysis of the association between Body Mass Index (BMI) and CD4
count stratified by Baseline VL and Delayed entry into care among HIV-infected individuals in
South Carolina diagnosed between 1997 and 2010.
Model
Parameter
Parameter
Parameter
Parameter
Estimate (SE)- Estimate (SE)Estimate (SE)Estimate (SE)Baseline VL <
Baseline VL >
Delayed entry
Delayed entry
100,000
100,000
into care < 3
into care > 3
months
months
Model 5 (Full model)
Time
4.0 (0.003) a
5.3 (0.006) a
2.4 (0.004) a
6.5 (0.003) a
BMI
Obese
63.4 (0.4) a
-33.1 (0.1) a
-18.6 (0.08) a
-30.1 (0.2) a
a
a
a
Overweight
119.0 (0.08)
-97.8 (0.4)
-9.5 (0.2)
74.3 (0.08) a
Normal
*
*
*
*
Time*BMI
time*Obese
-7.4 (0.01) a
7.0 (0.008) a
-3.9 (0.006) a
-0.7 (0.4) a
time*Overweight
a
a
a
-5.8 (0.5)
-6.9 (0.008)
-5.3 (0.009)
-7.9 (0.005) a
time*Normal
*
*
*
*
Abbreviations: SE, standard error; VL, viral load
a
p-value <0.001
Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2)

*Normal BMI category was used as the reference category.
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Differences in Adjusted Mean CD4 Counts

Figure 4.1: Adjusted CD4 count means by Body Mass Index (BMI) category
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Figure 4.2: Differences in adjusted CD4 count means by Body Mass Index (BMI) category
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CHAPTER 5
LONGITUDINAL ASSOCIATION OF THE INTERACTION OF GENDER AND
BODY MASS INDEX (BMI) ON HIV DISEASE PROGRESSION

5.1 Introduction
Evidence to support an association between gender and HIV progression has
varied. Some studies have found no association between gender and HIV progression,
reporting that progression to AIDS was similar between men and women as was the risk
of developing a CD4 cell count below 200 cells/mm3 and the risk of dying of AIDS.11 68
However, other studies have reported differences in CD4 count by gender.8 14-16 25 69 PreHAART, progression to AIDS and to death was marginally slower in women than in
men, suggesting higher CD4 cell counts offer no significance.15 After HAART initiation,
women had higher CD4 counts and the difference in CD4 count between men and women
increased over time.8 14 16 25 69 Some studies report that women were more likely to
experience an HIV/AIDS-related event compared to men and had an increased risk of
death even after adjustment for HAART use.16 However, a recent study reported that
post-HAART women have lower risks of HIV-AIDS-related events such as AIDS
dementia, tuberculosis and Karposi’s sarcoma.8 While gender differences in HIV
progression could be due to disparities in access to care, adherence, or retention, other
factors such as BMI may play a greater role in explaining the difference.
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Earlier studies that have assessed the relationship between BMI and HIV
progression have produced mixed results. Pre-HAART research has shown either no
association20 22 or that HIV-infected individuals with higher BMI levels are less likely to
progress to AIDS and die as compared to those individuals with normal weight (BMI: ≤
24.9 kg/m2).17 24 60 However, in the post-HAART era, the overweight and obese
categories may be differentially associated with disease progression and survival. It is
unclear whether this association is different in females and males. While the calculation
of BMI is not gender specific, the immune response to weight can be gender specific and
could explain the difference in immunological response to HIV, treatment, and disease
progression between men and women.70
This study is essential since it was conducted in the southern United States, an
area that suffers from one of the highest burdens of HIV-infected individuals,1 and
overweight and obese individuals.19 It investigates the gender differences in the
longitudinal association of BMI at HIV diagnosis with disease progression as evaluated
by CD4 counts obtained during routine medical care. To our knowledge, this is the first
study to determine whether the association between BMI and HIV progression differs by
gender.
5.2 Methods
Study Participants
Individuals included in this cohort study received care at the Ryan White Clinic in
Columbia, SC. Participants were eligible if they were diagnosed with HIV-infection from
January 1, 1997 through December 31, 2010, were at least 18 years of age, had weight
and height measurements within three months of HIV diagnosis, were HAART-naïve,
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and had at least one follow-up visit (within six months) after entering into care. Pregnant
individuals and those diagnosed with AIDS at the initial visit were excluded. This study
was approved by the University of South Carolina Institutional Review Board.
The power analysis, using the difference between mean CD4 counts by BMI
category from past research, determined that at least 85 HIV-infected individuals are
needed in each group to ensure an 80% power for the study. Investigators abstracted deidentified data from 409 medical records. However, since there were only 13 underweight
(BMI: <18.5 kg/m2) HIV-infected individuals and 2 transgendered HIV-infected
individuals, they were excluded from the analyses. A total of 394 individuals were
included in the final analyses.
Variables
Outcome: CD4 cell count (cells/mm3) was the outcome evaluated for this study
and was assessed over the course of medical care follow-up. CD4 cell count was used to
stage disease and is examined routinely by providers to determine when to initiate
HAART and to assess response to treatment. CD4 cell count was used as a continuous
variable in the analysis.
Exposure: Body mass index at diagnosis and gender were the main exposure
variables. BMI was estimated by dividing weight in kg by height (measured at diagnosis)
in m2 measured within three months after diagnosis, and was grouped into three
categories: normal (<25 kg/m2), overweight (25-29.5 kg/m2), and obese (≥30 kg/m2).
Gender was grouped as male and female.
Time varying covariates: HIV viral load (VL) (copies/mL) was collected at
diagnosis and monitored over the course of follow-up to assess ongoing response to
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treatment. HAART use was defined as any prescription for HIV medication over the
course of medical care. All data was extracted from the participants’ medical records.
Other variables recorded at baseline include age, race/ethnicity, marital status,
education, type of insurance, use of case management, alcohol use, smoking status, drug
use, mode of transmission, and delayed entry into care (defined later). Age was grouped
into the following five categories when included in the multivariate analysis: < 20; 2029; 30-39; 40-49; 50-59; and > 60. The following categories were used for race/ethnicity:
White, non-Hispanic; Black, non-Hispanic; Hispanic; Other; and Unknown. Education
was grouped into these categories: no high school diploma, high school diploma,
associate degree, bachelor degree, master’s degree, or doctoral degree. Type of insurance
was based on primary insurance and was clustered into these categories: Medicare;
Medicaid; Private Insurance or none (includes individuals enrolled in the AIDS Drug
Assistance Program). Mode of transmission was grouped into four categories:
heterosexual, men who have sex with men (MSM), injection drug users, or no identified
risk/no reported risk (NIR/NRR). Given that timely linkage to care has the potential to
improve health outcomes and prevent secondary HIV transmission,61 the delayed entry
into care variable was used as a covariate to adjust for differences between those who
seek care early versus those who do not. Delayed entry into care was determined by
subtracting the date of diagnosis from the date of first visit to the clinic, and was grouped
into the two categories: ≤3 months and ˃3 months.62 When an individual is diagnosed
with HIV at the Ryan White Clinic, he or she is offered the services of a case manager to
help the individual access care and other support services. Case management was defined
as present if the individual had an assigned case manager and absent otherwise. We
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adjusted for this variable because there may be a difference in clinical care outcome
associated with case management status. Current alcohol use, current smoking status, and
current drug use were all assessed by yes or no questions. Visit number was entered into
the analysis to control for time in study and was measured in months. Therefore, the first
visit represented time point one, the second visit represented time point two, and so forth.
Statistical Analyses
Demographic and clinical characteristics of the participants were compared across
the two gender categories, using means and standard error (SE) for continuous variables
and number (n) and percent (%) for categorical variables. Differences in clinical
characteristics were compared using t-test for continuous variables and Pearson χ2,
Fisher’s exact, or Kruskal-Wallis tests for categorical variables as appropriate.
To determine the effects of BMI at diagnosis and gender on longitudinal CD4 cell
counts, data were analyzed using mixed regression models and were stratified by gender.
Age group, race/ethnicity, use of case management, marital status, education, insurance
type, delayed entry into care, mode of transmission, alcohol use, smoking status, drug
use, CD4 count at diagnosis, and HIV VL at diagnosis and overtime were all adjusted for
in the analysis given their relationship to BMI or HIV progression. The mixed model
analysis was also stratified by baseline VL and delayed entry into care. For this analysis,
baseline VL was grouped into ≤100,000 copies/mL plasma and ˃100,000 copies/mL
plasma. Adjusted CD4 count means were determined and graphed at five different time
points by using an lsmeans statement in the mixed regression model, with tukey option to
determine differences between BMI categories by gender. The five time points were
determined from quantiles obtained from a univariate analysis. Sensitivity analyses were
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conducted to test whether loss to follow-up (i.e. those with > 6 months after the last
documented visit) impacted the results and the data were re-analyzed using the inverseprobability weighting method as suggested by Robins et al.63 Statistical analyses were
performed using SAS 9.2 (SAS Institute; Cary, North Carolina). For all analyses, the αlevel was set at 0.05.
5.3 Results
The study population’s mean BMI was 27.4 kg/m2 and was higher in females
(30.1 kg/m2) than in males (25.8 kg/m2). Gender was not related to age, race, educational
attainment, use of case manager, smoking, and delayed entry into care. However, BMI,
marital status, insurance, alcohol use, drug use, mode of transmission, HAART use, CD4
count at diagnosis, and HIV viral load at diagnosis were all significantly different among
the gender categories. Females were more likely to be older (35.3 years of age), to be
overweight (43.0% versus 16.8%), receive care after three months of diagnosis (57.7%
versus 56.3%) have a higher overall mean CD4 count at diagnosis (551.4 cells/mm3 ), and
a lower log HIV viral load at diagnosis (8.7 logs) compared to males.
BMI and CD4 count (longitudinal)
Follow-up time was similar across gender (P=0.074), although females (7.5 years)
had a marginally higher follow-up time compared to males (6.6 years). CD4 count mean
was higher in females (517.3 cells/mm3) than in males (473.6 cells/mm3).
A mixed model was analyzed to determine whether CD4 count change over time
is different among BMI between males and females (Table 2). There were significant
differences in mean CD4 count for the overweight and obese categories when compared
to the normal weight category among males and females. Among males, compared with
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the normal weight individuals in the full model, the obese category had significantly
larger increases in CD4 count (6.1 cells/mm3, P = <0.001) versus the overweight
category (0.5 cells/mm3 , P = <0.001). Among females, compared with the normal weight
individuals in the full model, the obese category had significantly larger increases in CD4
count (4.9 cells/mm3, P = <0.001) versus the significant decrease in CD4 count in the
overweight category (-2.9 cells/mm3, P = <0.001). For an example, after visit one, it is
predicted that obese HIV-infected females at diagnosis will experience a 4.9 cells/mm3
increase in CD4 count, while overweight HIV-infected females will experience a 2.9
decrease in CD4 count. The obese males had larger increases in CD4 count over time
compared to obese females, but the overweight females had larger decreases in CD4
count over time compared to the increase in overweight males. The results of the
sensitivity analyses using the inverse-probability weighting method to account for loss to
follow up (n=73) were qualitatively similar to the results presented.
Overall, mean CD4 count increased over time for females and males. Figure 1
shows a significant interaction between BMI and CD4 count using the adjusted mean
CD4 counts. The adjusted mean CD4 count was higher at the outset for the obese males,
followed by overweight females and males. Over time the CD4 count trend increased
among all groups, except the overweight female category, which decreased over time
(Figure 1). The second graph (B) displays the differences in adjusted mean CD4 counts
when compared to the normal weight group. The overweight males and females had the
greatest difference in adjusted mean CD4 counts when compared to the normal weight
males and females. The adjusted mean CD4 counts at each visit were not statistically
different from the normal weight group’s adjusted means.
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The mixed model analysis among those with lower baseline VL values (<100,000
copies/mL plasma) showed a significant change in CD4 count over time between BMI
categories among males and females (Table 3). In males, significantly larger increases in
CD4 count were seen in the obese category (3.8 cells/mm3) versus the overweight
category who experienced decreases in CD4 count (-1.2 cells/mm3). In females,
significantly larger increases in CD4 count were seen in the obese category (3.4
cells/mm3) versus the overweight category who experienced decreases in CD4 count (-3.8
cells/mm3). Among those with higher baseline VL values (>100,000 copies/mL plasma),
significant changes in CD4 count over time was seen between BMI categories among
males and females. In males, significantly larger decreases in CD4 count were seen in the
obese category (-2.6 cells/mm3) and the overweight category (-0.5 cells/mm3). In
females, significant decreases in CD4 count were seen in the obese category (-13.2
cells/mm3) and the overweight category (-2.0 cells/mm3).
For those individuals who entered care within three months of diagnosis,
significant changes in CD4 count over time was seen in the BMI categories when
compared to the normal weight patients among males and females (Table 3). In males,
significant increases in CD4 count were seen in the obese category (1.2 cells/mm3) versus
the overweight category that experienced decreases in CD4 count (-0.3 cells/mm3). In
females, significantly larger increases in CD4 count were seen in the obese category (3.3
cells/mm3) versus the overweight category that experienced decreases in CD4 count (-4.0
cells/mm3). In those who received care after three months of diagnosis, significant
changes in CD4 count over time was seen in the BMI categories when compared to the
normal weight patients among males and females. In males, significantly larger increases
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in CD4 count were seen in the obese category (2.6 cells/mm3) versus the overweight
category that experienced decreases in CD4 count (-10.3 cells/mm3). In females,
significant increases in CD4 count were seen in the obese (9.9 cells/mm3) versus the
overweight category that experienced decreases in CD4 count (-2.3 cells/mm3) when
compared to the normal weight category.
5.4 Discussion
This cohort of HIV–infected individuals experienced CD4 counts that were
highest at time of diagnosis among obese females, followed by overweight females and
obese males. Over time, CD4 count increases were highest for the obese males, followed
by the obese females and overweight males, but decreased for overweight females. While
high BMI among HIV-infected individuals is linked to increased CD4 count over time in
males and females, moderately high BMI was not, particularly among females. This
implies that the immune recovery gained from HAART and the effect is different among
males and females.
Several studies reported that obese HIV-infected individuals had better survival
over time.22 24 60 Shor-Posner et al. study population included men (n=82) and women
(n=43) and had a higher proportion of obese men (69.6%) than obese females (30%).
They discovered that CD4 cell count over time was higher for obese individuals
compared with the non-obese group (376 cells/mm3 vs. 364 cells/mm3), although not
statistically significant.22 Another study included only women (n=871) and reported a
significant difference in CD4 count among BMI categories, with the overweight group
experiencing larger increases in CD4 counts, followed by those of normal weight and
underweight.24 The results of this study were different from the women in our study.
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Shuter et al. study population included men (n=103) and women (86) and also had a
higher proportion of women (32.5%) who were overweight compared to men (12.6%).
They learned that overweight individuals progressed more slowly to AIDS, and CD4
count was not independently predictive of progression to AIDS. 60
A post-HAART study recently investigated the relationship between BMI and
HIV progression by following HIV-infected men (n=712) and women (n=203) starting
treatment between 1998 and 2008 and discovered that overweight HIV-infected
individuals experienced a 12-month CD4 count gain in women (+ 9 cells/ uL), but not in
men (-1 cells/uL), while the normal weight (-65 cells/uL) and obese categories (-12
cells/uL) experienced a reduction.25 In addition, they learned that the interaction of sex
and BMI did not appear to be an important determinant of CD4 count change (P=0.16),
which is different from our study results. Our study determined that the association
between BMI and CD4 count change over time is distinct in men and women, with a
significantly larger increase in CD4 counts in obese men compared to obese women.
One researcher proposed that there may be an ideal BMI range for immune
recovery once on treatment for a year, with immune reconstitution reaching a plateau in
the range of BMI 25 to 30 kg/m.2 25 This could explain why overweight individuals are
experiencing higher mean absolute CD4 counts compared to obese individuals. A recent
post-HAART study included men (n=1556) and women (n=126) and reported that, obese
HIV-infected individuals had smaller increases in CD4 counts (+69 cells/mm3) compared
to those in the overweight (+116 cells/mm3) and normal weight categories (+102
cells/mm3).54
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The following explanations could validate our results. First, hormones,
particularly estrogen, may be responsible for fat distribution and storage in non-HIV
populations and could explain the difference in immune response in HIV-infected men
and women.70 71 Secondly, women reportedly have healthier behaviors and higher
adherence rates to medication, which could explain higher overall mean CD4 count.8 The
women in our study had a higher CD4 count and lower VL at diagnosis compared to
men, but were less likely to be on HAART. However, overweight males who had a
baseline VL ≤100,000 and who entered care within three months of diagnosis had higher
increases in CD4 count compared to overweight females. Thirdly, leptin is a satiety
hormone that circulates directly proportional to weight.64 Leptin is also known to increase
with inflammation. Obese individuals have a higher concentration of leptin compared to
overweight and normal weight individuals. Given HIV causes inflammation and CD4
cells have leptin receptors and has a proliferation effect, it could explain the increase or
higher levels of CD4 among obese individuals. Fourthly, obesity is surplus of energy in
the form of stored fat. 19 Obesity spares protein from being used as an energy source,
which aids in maintaining immune function and helps to offset the high metabolic rate of
HIV. This could explain the protective effect of obesity on CD4 levels. Lastly, some
proclaim that since untreated HIV-infection is associated with weight loss, individuals in
the normal weight category are a mixed group consisting of both individuals who were
normal weight pre-diagnosis, and those who were overweight but lost weight because of
HIV-infection in the period preceding their diagnosis.24 This is an example of reverse
causality and a potential confounder in all studies evaluating this question.
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To avoid weight change being mis-classified into another BMI category, height
and weight was collected within three months of diagnosis. If reverse causality is
contributing to the association between BMI and HIV progression, then the BMI
characteristics of the source population are likely important. As HIV is diagnosed at an
earlier stage, before wasting sets in, the HIV-infected population is similar to the general
population with respect to BMI. In our study population the mean BMI was 27.4 kg/m2 ,
and overweight and obesity prevalence was 30% and 26.8%, which is similar to the
prevalence of overweight (35.4%) and obesity (31.5%) in general HIV-uninfected
population in South Carolina.19 Similar characteristics were discovered between our
study population and all HIV-infected individuals in the entire state of South Carolina,
with respect to race (Black: 74.2% versus 76%) and mode of transmission (MSM: 33.1%
versus 37.1%).66 Given the comparisons between our study cohort and the overall HIVinfected population in South Carolina, reverse causality most likely did not influence our
results.
Several limitations may have impacted our results. First, we were unable to make
an hypothesis that included the underweight BMI category. Nonetheless, past research
has shown that underweight individuals normally have a faster progression to AIDS and
death compared to other BMI categories.17 24 25 Second, the treatment variable only
measured whether individuals received HAART throughout the course of their HIV
infection. We did not assess time spent on HAART. Third, the secular change of CD4
count is impacted as more HIV-infected individuals are prescribed HAART and
medication efficacy has increased, which could potentially attenuate the associations.68
Fourth, our population consisted of mostly black HIV-infected individuals and the results
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may not be generalizable to other populations. Fifth, the alcohol use and drug use
variables only captured whether individuals were socially participating in these factors
and not the frequency of use. Sixth, we did not collect any information on gynecological
factors (i.e. contraception use, menopause status) that could potentially confound our
results. Finally, there is the likelihood of residual confounding such as measurement error
of a particular variable.
Our study has several strengths. First, we examined the post-HAART longitudinal
association between BMI at baseline and HIV progression in a southern state. In contrast,
the majority of other studies from other regions focused on survival rather than
continuous immune function. Second, unlike previous research, we adjusted for many
potential confounders including delayed entry into HIV medical care and use of case
management. Entry into HIV medical care is essential for access to antiretroviral therapy
and facilitates the delivery of important prevention education to reduce HIV transmission.
In addition, retention in care is necessary to monitor response to therapy. Therefore,
adjusting for delayed entry into care is important to accurately determine the association
between BMI and HIV progression as it relates to both. Whereas our results were similar
to Koethe’s et al. results in regards to mean CD4 counts, they were not able to adjust for
educational attainment or insurance type.25 The current study was able to gain an
improved estimation of the relationship between BMI at diagnosis and CD4 count over
time by adjusting for these variables. Third, our population of individuals with different
stages of HIV disease, allows us to determine if the relationship under study exists in
HIV-infected individuals with different levels of immune impairment. Fourth, this
investigation includes fourteen years of follow-up (i.e. those diagnosed in 1997) allowing
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us to assess CD4 count over a long period. Finally, the inverse probability weighting
method used to evaluate the possible impact of loss to follow-up provided materially
similar results to those reported.
Our study demonstrated that male HIV-infected individuals who were obese at
diagnosis had greater increases in CD4 counts over time when compared to female HIVinfected individuals who were obese at diagnosis. Although obese males experience
higher CD4 count increases over time, obese females who seek care early and have a
lower at diagnosis VL experience a better prognosis of HIV. This suggests that
innovative strategies are needed to determine ways to improve differences in immune
response between genders. Future studies should evaluate differences in hormonal
activity on CD4 counts over time between genders, especially among females, to learn
more about the difference in progression between males and females.
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Table 5.1: Baseline characteristics of South Carolina HIV-infected
individals diagnosed between 1997 and 2010 by Gender.

Overall (n=394)
Characteristic
Age
Body Mass Index
Obese
Overweight
Normal
Race
White
Black
Hispanic
Other
Marital Status
Single
Married
Divorced
Widowed
Partnered
Unknown
Education
No HS Diploma
High School Diploma
Associate Degree
Bachelor Degree
Master’s Degree
Doctorate Degree
Unknown
Insurance
Medicare
Medicaid
Private Insurance
None
Followed by Case Manager
Yes
No
Alcohol Use
Yes
No
Unknown
Smoking
Yes
No
Unknown
Drug Use
Yes
No
Unknown
Mode of Transmission
Heterosexual
MSM

Male
(n=245)
34.9 ± 10.4

Pa

Female
(n=149)
35.3 ± 10.9

0.684

126 (51.4%)
41 (16.8%)
78 (31.8%)

44 (29.5%)
64 (43.0%)
41 (27.5%)

<0.001

65 (26.5%)
172 (70.2%)
3 (1.2%)
5 (2.0%)

25 (16.8%)
122 (81.9%)

163 (66.5%)
19 (7.8%)
36 (14.7%)
6 (2.4%)
20 (8.2%)
1 (0.4%)

78 (52.3%)
28 (18.8%)
34 (22.8%)
8 (5.4%)
1 (0.7%)

<0.001

31 (12.7%)
100 (40.8%)
11 (4.5%)
16 (6.5%)
5 (2.0%)
2 (0.8%)
80 (32.7%)

31 (20.8%)
40 (26.8%)
12 (8.0%)
8 (5.4%)
4 (2.7%)
1 (0.7%)
53 (35.6%)

0.071

41 (16.7%)
9 (3.7%)
58 (23.7%)
137 (55.9%)

29 (19.5%)
34 (22.8%)
37 (24.8%)
49 (32.9%)

<0.001

105 (42.9%)
140 (57.1%)

65 (43.6%)
84 (56.4%)

0.882

179 (73.0%)
58 (23.7%)
8 (3.3%)

62 (41.6%)
78 (52.4%)
9 (6.0%)

<0.001

145 (59.2%)
91 (37.1%)
9 (3.7%)

72 (48.3%)
69 (46.3%)
8 (5.4%)

0.104

99 (40.4%)
137 (55.9%)
9 (3.7%)

42 (28.2%)
98 (65.8%)
9 (6.0%)

0.039

92 (37.5%)
123 (50.2%)

135 (90.6%)

2 (1.3%)
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0.090

IDU
NIR/NRR
Delayed entry into care
< than 3 months
> than 3 months
HAART use
Yes
No
CD4 count at diagnosis

16 (6.6%)
14 (5.7%)

4 (2.7%)
10 (6.7%)

<0.001

107 (43.7%)
138 (56.3%)

63 (42.3%)
86 (57.7%)

0.787

223 (91.0%)
22 (9.0%)
465.6 ± 218.4

124 (83.2%)
25 (16.8%)
551.4 ± 297.2

0.021

<0.001
Log HIV Viral Load at
4.3 ± 0.9
3.8 ± 1.0
<0.001
diagnosis
NOTE: Mean and standard deviation are shown for Body mass Index, Age,
CD4 count at diagnosis, HIV Viral Load at diagnosis; Transgender was not
included in the table.
Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2)
a

Comparison between baseline BMI and gender stratas
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Table 5.2: Mixed Model Analysis of the association between Body Mass
Index (BMI) and CD4 count among HIV-infected individuals diagnosed in
South Carolina between 1997 and 2010 stratified by Gender.
Model
Parameter
Standard
Pb
a
Estimate
Error (SE )
MALES
Full Model
5.2
0.003
<0.001
Time
BMI
-4.9
0.1
<0.001
Obese
43.1
0.09
<0.001
Overweight
*
*
*
Normal
time*BMI
0.4
0.007
<0.001
time*Obese
-5.7
0.006
<0.001
time*Overweight
*
*
*
time*Normal
FEMALES
Full Model
3.0
0.005
<0.001
Time
BMI
-123.9
0.1
<0.001
Obese
94.5
0.1
<0.001
Overweight
*
*
*
Normal
time*BMI
1.9
0.008
<0.001
time*Obese
-5.9
0.007
<0.001
time*Overweight
*
*
*
time*Normal
NOTE: * Normal BMI category was used as the reference group. The parameter estimates
represent the difference in the adjusted mean CD4 count by BMI category. Those
overweight has higher mean CD4 counts.
Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2)
a SE=Standard Error
b Comparison between baseline BMI categories
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Table 5.3: Mixed Model Analysis of the association between Body Mass Index (BMI) and CD4 count
stratified by Baseline VL and Delayed entry into care among HIV-infected individuals in South
Carolina diagnosed between 1997 and 2010 by Gender.
Model
Parameter
Parameter
Parameter
Parameter
Estimate (SE)- Estimate (SE)Estimate (SE)Estimate (SE)Baseline VL <
Baseline VL >
Delayed entry
Delayed entry
100,000
100,000
into care < 3
into care > 3
months
months
Model 5 (Full model)
Males
4.6 (0.004) a
5.8 (0.006) a
7.5 (0.004) a
2.2 (0.004) a
Time
BMI
-46.9 (0.1) a
154.7 (1.2) a
-1.7 (0.1) a
-205.7 (0.4) a
Obese
a
a
a
117.7 (0.1)
510.7 (0.4)
64.0 (0.1)
256.3 (0.4) a
Overweight
*
*
*
*
Normal
Time*BMI
-0.8 (0.009) a
-8.4 (0.02) a
-6.3 (0.01) a
0.4 (0.01) a
time*Obese
a
a
a
-5.8 (0.006)
-6.3 (0.01)
-7.8 (0.006)
-12.5 (0.03) a
time*Overweight
*
*
*
*
time*Normal
Females
3.9 (0.005) a
-5.8 (0.06) a
2.4 (0.005) a
2.0 (0.01) a
Time
BMI
32.9 (0.1) a
-42.8 (1.4) a
-137.1 (0.2) a
-431.8 (2.5) a
Obese
a
a
a
-96.2 (0.2)
-114.4 (1.6)
32.4 (0.2)
-135.6 (2.7) a
Overweight
*
*
*
*
Normal
Time*BMI
-0.5 (0.008) a
-7.4 (0.08) a
0.9 (0.009) a
7.9 (0.02) a
time*Obese
a
a
a
-6.1 (0.007)
3.8 (0.06)
-6.4 (0.008)
-4.3 (0.02) a
time*Overweight
*
*
*
*
time*Normal
Abbreviations: SE, standard error; VL, viral load
Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2)
a

p-value <0.001
*Normal BMI category was used as the reference category.
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Adjusted Mean CD4 Counts by BMI Category and Gender
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Figure 5.1: Adjusted CD4 count means by BMI and Gender Categories
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Figure 5.2: Differences in adjusted CD4 count means by BMI and Gender categories
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CHAPTER 6
LONGITUDINAL CHANGES IN CARDIOVASCULAR DISEASE RISK
MARKERS AND THEIR ASSOCIATION WITH BODY MASS INDEX (BMI) IN
HIV-INFECTED INDIVIDUALS

6.1 Introduction
Once highly active antiretroviral treatment (HAART) was initiated, the wasting
syndrome became a decreased presence among HIV-infected population. One of the
complications related to HAART was weight gain, which lead to an increased prevalence
of overweight and obesity among HIV-infected individuals.1 21 Approximately two out of
every three adults are overweight (i.e. BMI = 25-29.9) and more than one-third of adults
are obese (i.e. BMI ≥30), with non-Hispanic blacks having the highest age-adjusted rates
of obesity in the US.19 South Carolina (30.8%) is one of thirteen states that have a
prevalence of obesity equal to or greater than 30% in the general population. Some
studies have reported a lower prevalence of obesity among HIV-infected populations
versus the general population,52 53 whereas others have reported a higher prevalence.24 30
Although the effect of HAART in causing obesity in HIV-infected patients may result in
a moderately slower progression to AIDS due to the survival gain afforded by elevated
BMI,24 an increase in non-AIDS related outcomes, including metabolic abnormalities,
have developed and has led to increased risk of morbidity and mortality.54
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Abdominal obesity, hyperlipidemia, hypertension, and insulin resistance are
examples of these abnormalities.55 One of the primary causes for the rising prevalence of
the abnormalities is the rising prevalence of overweight and obesity in non-HIV and
HIV-infected individuals, leading to an increased chance of developing adverse
cardiovascular outcomes such as myocardial infarction and stroke. 21 As suggested by
some studies, inflammation caused by the long-term effects of HIV or HAART may also
play a greater role in causing these outcomes among HIV-infected individuals,
particularly because inflammation is known to be predictive of cardiovascular disease
(CVD) outcomes among non-HIV populations.72 73
One study reported that BMI was useful in predicting cardiovascular disease
(CVD) risk among their HIV population.28 Given the increased risk of CVD outcomes in
non-HIV obese individuals, it is important to study this association among various HIVinfected populations and determine if this association is differentially affected between
BMI categories. The importance of this study is that it was conducted in the southern
United States, a region that has the highest prevalence of HIV-infected individuals,1
overweight and obese individuals, and cardiovascular disease.19 A limited number of
studies have evaluated the changes in metabolic abnormalities over time by BMI group.
This study investigates the longitudinal association of BMI at HIV diagnosis with
metabolic abnormalities as evaluated by markers of cardiovascular disease (i.e. fasting
blood glucose, high-density lipoprotein (HDL) and low-density lipoprotein (LDL), and
systolic and diastolic blood pressure measurements) obtained during routine medical
care.
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6.2 Methods
Study population and procedure
Individuals included in this cohort study received care at the Ryan White Clinic in
Columbia, SC. Eligible participants were diagnosed with HIV-infection from January 1,
1997 through December 31, 2010, were at least 18 years of age, had weight and height
measurements within three months of HIV diagnosis, were HAART-naïve, and had at
least one follow-up visit (within six months) after entering into care. Individuals were
excluded if pregnant when diagnosed or diagnosed with AIDS at the initial visit. The
University of South Carolina Institutional Review Board approved this study.
Using the difference between mean CD4 counts by BMI category from past
research, the power analysis determined that at least 85 HIV-infected individuals are
needed in each group to ensure an 80% power for the study. Investigators extracted deidentified data from 409 medical records. However, since there were only 13 underweight
(BMI: <18.5 kg/m2) HIV-infected individuals, this category was excluded from the
analyses. A total of 396 individuals were included in the final analyses.
Variables
Outcome: Five outcomes were evaluated for this study: Fasting blood glucose
(mg/dL), HDL (mg/dL), LDL (mg/dL), Systolic blood pressure (SBP) (mmHg), and
Diastolic blood pressure (DBP) (mmHg) levels were assessed over the course of medical
care follow-up. These outcomes were used to determine risk of illness and cardiovascular
disease, and the effects of HIV alone and with HAART. Each outcome was used as a
continuous variable in the analysis.
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Exposure: The main exposure variable was BMI at diagnosis and was estimated
by dividing weight in kg by height (measured at diagnosis) in m2 measured within three
months after diagnosis. BMI was grouped into three categories: normal (<25 kg/m2),
overweight (25-29.5 kg/m2), and obese (≥30 kg/m2).
Time varying covariates: CD4 cell count (cells/mm3) and HIV viral load (VL)
(copies/mL) were collected at diagnosis and monitored over the course of follow-up to
estimate disease stage, to determine when to start HAART, and to assess ongoing
response to treatment. Fasting blood glucose, HDL, LDL, SBP, and DBP were also
collected at diagnosis. HAART use and any medication prescribed for abnormalities in
HDL/LDL, SBP/DBP measurements, and blood glucose levels were defined as any
prescription for HIV medication, hyperlipidemia, hypertension or diabetes respectively,
over the course of medical care. All data was extracted from the participants’ medical
records.
Additional variables documented at baseline include age, gender, race/ethnicity,
marital status, education, type of insurance, use of case management, alcohol use,
smoking status, drug use, mode of transmission, and delayed entry into care (defined
later). Age was categorized into the following five categories when included in the
multivariate analysis: < 20; 20-29; 30-39; 40-49; 50-59; and > 60. The following
categories were used for race/ethnicity: White, non-Hispanic; Black, non-Hispanic;
Hispanic; Other; and Unknown. Education was grouped into these categories: no high
school diploma, high school diploma, associate degree, bachelor degree, master’s degree,
or doctoral degree. Type of insurance was based on primary insurance and was clustered
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into these categories: Medicare; Medicaid; Private Insurance or none (includes
individuals enrolled in the AIDS Drug Assistance Program). Mode of transmission was
grouped into four categories: heterosexual, men who have sex with men (MSM),
injection drug users, or no identified risk/no reported risk (NIR/NRR). Timely linkage to
care is likely to improve health outcomes and prevent secondary HIV transmission, 61
thus the delayed entry into care variable was added as a covariate to adjust for differences
between those who seek care early versus those who do not. Delayed entry into care was
determined by subtracting the date of diagnosis from the date of first visit to the clinic,
and was categorized into two categories: ≤3 months and ˃3 months.62 The services of a
case manager are offered when a HIV-infected individual is referred to care and to help
the individual access care and other support services. Case management was defined as
present if the individual had an assigned case manager and absent otherwise. We adjusted
for this variable because there may be a difference in clinical care outcome associated
with case management status. Current alcohol use, current smoking status, and current
drug use were all assessed by yes or no questions. Visit number was entered into the
analysis to control for time in study, which was measured in months. Therefore, the first
visit represented time point one, the second visit represented time point two, and so forth.
Statistical Analyses
Demographic and clinical characteristics of the participants were compared across
the three BMI categories, using means and standard error (SE) for continuous variables
and number (n) and percent (%) for categorical variables. Differences in clinical
characteristics were compared using t-test for continuous variables and Pearson χ2,
Fisher’s exact, or Kruskal-Wallis tests for categorical variables as appropriate.
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To determine the association between BMI at diagnosis and the five metabolic
abnormalities, data were analyzed using mixed regression models. Age group,
race/ethnicity, gender, use of case management, marital status, education, insurance type,
delayed entry into care, mode of transmission, alcohol use, smoking status, drug use,
fasting blood glucose at diagnosis, HDL and LDL at diagnosis, and SBP and DBP
measurements at diagnosis, HAART use, other medication uses, CD4 count at diagnosis
and overtime, and HIV VL at diagnosis and overtime were all adjusted for in the analysis
given their relationship to BMI and/or the metabolic abnormalities. The adjusted means
for each outcome were calculated and graphed at five different time points by using an
lsmeans statement in the mixed regression model, with tukey option to determine
differences between BMI categories. The five time points were determined from
quantiles obtained from a univariate analysis. Sensitivity analyses were conducted to test
whether loss to follow-up (i.e. those with > 6 months after the last documented visit)
impacted the results and the data were re-analyzed using the inverse-probability
weighting method as suggested by Robins et al.63 Statistical analyses were performed
using SAS 9.2 (SAS Institute; Cary, North Carolina). For all analyses, the α-level was set
at 0.05.
6.3 Results
Baseline Characteristics
The study population was considered overweight, with a 27.4 kg/m2 mean
baseline BMI, and mean age was 35 years. This cohort was primarily male (61.9%),
black (74.2%), and single (61.1%); approximately 35.3% had at least a high school
diploma, 47.2% did not have insurance, 57.1% were not followed by a case manager,

78

60.9% used alcohol, 54.8% smoked, 59.8% did not report drug use, 55.8% were
heterosexual, 56.8% entered care > 6 months of diagnosis, and 88.1% were prescribed
HAART throughout course of medical care (Table 1).
BMI categories were similar in regards to age, race/ethnicity, marital status,
educational attainment, type of insurance, use of case manager, HAART use, cholesterol
medication, blood glucose at diagnosis, HDL at diagnosis, LDL at diagnosis, SBP at
diagnosis, and DBP at diagnosis. However, significant differences among the BMI
categories were found in gender, alcohol use, smoking status, drug use, mode of
transmission, delayed entry into care, CD4 count at diagnosis, HIV VL at diagnosis,
diabetic medication, and BP medication. When compared to the normal and overweight
HIV-infected individuals, obese HIV-infected individuals were more likely to be female
(60.4%), non-alcohol users at diagnosis (44.3%), to be non-smokers (53.8%), and had the
lowest HIV VL at baseline (4.5 logs), and the highest CD4 count at baseline (575.6
cells/mm3), highest fasting blood glucose at baseline (106.6 mg/dL), highest HDL at
baseline (49.2 mg/dL), highest SBP (130.7 mmHg), and highest DBP (83.3 mmHg).
BMI and fasting blood glucose over time
The overall mean follow-up time was 6.7 years and was similar across the BMI
categories (P=0.108). The overall mean for fasting blood glucose over time was 100.3
mg/dL. Mean fasting blood glucose was highest among obese individuals (108.8 mg/dL),
followed by overweight individuals (101.5 mg/dL) and normal weight individuals (95.2
mg/dL).
Figure 1 shows a significant interaction between BMI and fasting blood glucose.
The adjusted mean fasting blood glucose was higher at the outset for the obese category,
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but it decreased over time and was the lowest at the end of follow-up, followed by the
overweight and normal weight categories (Figure 1). When compared to the normal
weight category, differences in adjusted mean fasting blood glucose were greater among
the obese category than the overweight category.
Mixed models were used to determine whether the main effect of fasting blood
glucose and fasting blood glucose change over time was different among BMI categories
(Table 2). After adjusting for the variables listed in Table 1, there were statistically
significant differences in mean fasting blood glucose for the overweight and obese
categories when compared to the normal weight category. Compared with the normal
weight individuals in the full model, the obese category had significant decreases in
fasting blood glucose levels (-0.2 mg/dL, P = <0.001) versus the increase in fasting blood
glucose in the overweight category (0.1 mg/dL, P = <0.001). For an example, after visit
one, it is predicted that obese HIV-infected individuals at diagnosis will experience a 0.2
mg/dL decrease in fasting blood glucose, while overweight HIV-infected individuals will
experience a 0.1 increase in fasting blood glucose.
BMI and HDL over time
The overall mean for HDL over time was 48.1 mg/dL. Mean HDL was highest
among overweight individuals (50.6 mg/dL), followed by obese individuals (47.7 mg/dL)
and normal weight individuals (46.5 mg/dL).
Overall, HDL decreased slightly over time. Figure 2 shows a significant
interaction using between BMI and the adjusted mean HDL. While the HDL was higher
at the outset for the overweight and normal weight groups compared to the obese
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category, over time the obese group had a larger increase in HDL compared to the
overweight and normal weight categories (Figure 2). When compared to the normal
weight category, differences in adjusted mean HDL were greater among the obese
category than the overweight category.
Mixed models were used to determine whether the main effect of HDL and HDL
change over time was different among BMI categories (Table 2). After adjusting for the
variables listed in Table 1, there were statistically significant differences in mean HDL
for the overweight and obese categories when compared to the normal weight category.
Compared with the normal weight individuals in the full model, the obese (0.4 mg/dL, P
= <0.001) and overweight categories (0.26 mg/dL, P = <0.001) had significant increases
in HDL levels. For an example, after visit one, it is predicted that obese HIV-infected
individuals at diagnosis will experience a 0.4 mg/dL increase in HDL, while overweight
HIV-infected individuals will experience a 0.26 increase in HDL.
BMI and LDL over time
The overall mean for LDL over time was 110.5 mg/dL. Mean LDL was highest
among overweight individuals (116.1 mg/dL), followed by obese individuals (113.7
mg/dL) and normal weight individuals (104.8 mg/dL).
Overall, LDL decreased over time. Figure 3 shows a significant interaction
between BMI and the adjusted mean LDL. The overweight category had a higher LDL at
the outset and had the largest decrease in LDL over time, followed by the obese and
normal weight categories (Figure 3). When compared to the normal weight category,
differences in adjusted mean LDL were greater among the overweight category than the
obese category.
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Mixed models were used to determine whether the main effect of LDL and LDL
change over time was different among BMI categories (Table 2). After adjusting for the
variables listed in Table 1, there were statistically significant differences in mean LDL
for the overweight and obese categories when compared to the normal weight category.
Compared with the normal weight individuals in the full model, the obese (-1.0 mg/dL, P
= <0.001) and overweight categories (-1.4 mg/dL, P = <0.001) had significant decreases
in LDL levels. For an example, after visit one, it is predicted that obese HIV-infected
individuals at diagnosis will experience a 1.0 mg/dL decrease in LDL, while overweight
HIV-infected individuals will experience a 1.4 decrease in LDL.
BMI and SBP over time
The overall mean for SBP over time was 128.9 mg/dL. Mean SBP was highest
among obese individuals (132.0 mg/dL), followed by overweight individuals (130.3
mg/dL) and normal weight individuals (126.5 mg/dL).
Figure 4 shows a significant interaction between BMI and the adjusted mean SBP.
The adjusted mean SBP was higher at the outset and remained the highest for the
overweight category. Both the overweight and obese categories adjusted mean SBP
decreased over time, compared to the increase in the normal weight category (Figure 4).
When compared to the normal weight category, differences in adjusted mean SBP were
greater among the obese category than the overweight category.
Mixed models were used to determine whether the main effect of SBP and SBP
change over time was different among BMI categories (Table 2). After adjusting for the
variables listed in Table 1, there were statistically significant differences in mean SBP for
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the overweight and obese categories when compared to the normal weight category.
Compared with the normal weight individuals in the full model, the obese (-1.96 mg/dL,
P = <0.001) and overweight categories (0.96 mg/dL, P = <0.001) had significant
decreases in SBP levels. For an example, after visit one, it is predicted that obese HIVinfected individuals at diagnosis will experience a 1.96 mg/dL increase in SBP, while
overweight HIV-infected individuals will experience a 0.96 increase in SBP.
BMI and DBP over time
The overall mean for DBP over time was 81.6 mg/dL. Mean DBP was highest
among obese individuals (84.2 mg/dL), followed by overweight individuals (82.1 mg/dL)
and normal weight individuals (79.9 mg/dL).
Figure 5 shows a significant interaction between BMI and DBP. The adjusted
mean DBP was slightly higher at the outset for the normal category, followed by the
obese and overweight categories (Figure 5). However over time, the normal weight
category had a larger decrease in DBP, while the overweight and obese categories
experienced a slight decrease. When compared to the normal weight category, differences
in adjusted mean DBP were roughly the same among the obese category and the
overweight category.
Mixed models were used to determine whether the main effect of DBP and DBP
change over time was different among BMI categories (Table 2). After adjusting for the
variables listed in Table 1, there were statistically significant differences in mean DBP
for the overweight and obese categories when compared to the normal weight category.
Compared with the normal weight individuals in the full model, the obese category had
no change in DBP levels (0.0 mg/dL, P = <0.001) versus the slight decrease in DBP in
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the overweight category (-0.1 md/dL, P = <0.001). For an example, after visit one, it is
predicted that obese HIV-infected individuals at diagnosis will experience relatively no
change in DBP, while overweight HIV-infected individuals will experience a 0.1
decrease in DBP.
The mixed regression analysis results of the interaction between BMI category
and HAART use on CD4 count over time are listed in Table 3. Obese HIV-infected
individuals on HAART have significantly larger increases in fasting blood glucose (P =
<0.001) and HDL (P = <0.001), and significantly larger decreases in LDL (P = <0.001)
and SBP (P = <0.001) compared to overweight-HIV infected individual on HAART.
Overweight HIV-infected individuals on HAART have larger decreases in DBP (P =
<0.001) compared to obese HIV-infected individuals on HAART. The results of the
sensitivity analyses using the inverse-probability weighting method to account for loss to
follow up (n=73) were qualitatively similar to the results presented.
6.4 Discussion
The prevalence of overweight and obesity was considered high within this cohort,
with nearly 57% being overweight and obese. Fasting blood glucose, HDL, and blood
pressure levels were highest at time of diagnosis among those who were obese compared
to those in the overweight and normal weight categories. Over time, the obese category
had larger decreases in fasting blood glucose and SBP, and larger increases in HDL
compared to the overweight and normal weight categories. The overweight category had
larger decreases in LDL when compared to the obese and normal weight categories.
Higher BMI among HIV-infected individuals is associated with increased CD4 count
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over time and also appears to be protective against some cardiovascular disease risk
markers.
Obesity is known to be one of the causes of increased glucose levels, which can
result in the development of diabetes.19 Other risk factors include race, age, physical
inactivity, and family history of diabetes. Studies have shown that the incidence of
diabetes increases with cumulative exposure to HAART,41 particularly protease
inhibitors, and that the HIV-infected individuals tend to have a greater chance for the
development of diabetes morbidity when compared to HIV naïve patients.42 Evidence has
shown that HIV itself causes lipodystrophy, which can cause abnormally high levels of
blood glucose.74 One study reported an overall glucose mean of 87 mg/dL among their
cohort of HIV-infected individuals and stated that higher BMI was associated with higher
glucose concentrations.6 In contrast, our study had a higher overall mean of fasting blood
glucose (100.3 mg/dL) and had an overweight population, compared to the normal weight
population seen in the El Sadr et al. study. Additionally, our study evaluated fasting
blood glucose over time by looking at the difference between BMI categories. We
showed that while the obese category had a higher decrease in fasting blood glucose over
time compared to the increase among the overweight category, they both are significantly
lower than the normal weight category. Therefore, this population behaves dissimilar to
the non-HIV infected individuals where higher BMIs are associated with higher glucose
levels.
Morbidity related to HDL and LDL levels are also associated with obesity,56
although one study reported no association with LDL and that the negative association
between BMI and HDL levels could be explained by insulin resistance.75 While this may
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be true, this association is slightly different among HIV-infected individuals. El Sadr et
al. reports an overall HDL mean of 37 mg/dL and an overall LDL mean of 98.3 mg/dL,
and only found a significant association between BMI and LDL.6 Another study reported
that 44.7% of their population had low HDL-C levels (<40 mg/dL), an overall LDL mean
of 107.3, a negative significant association with BMI, and that low HDL-C levels were
associated with antiretroviral therapy.42 Our study had higher overall means for HDL and
LDL compared to their study. We also adjusted for glucose levels in the mixed regression
analyses and found significantly different associations between BMI and the lipid profiles
(HDL and LDL). Unlike non-HIV infected individuals, our study found that at a positive
association between the obese and overweight groups with HDL, and a negative
association between the obese and overweight group with LDL.
Increased blood pressure is associated with the risk factors that affect both lipid
levels and blood glucose levels, such as obesity among non-HIV infected individuals.57
Overweight and obese individuals have higher systolic and DBP levels. Among HIVinfected individuals, traditional risk factors are also associated with increased blood
pressure.36 Most studies report a prevalence of hypertension among HIV-infected
individuals to be between 25%-35% versus thirty-six percent of our population took
blood pressure medication for hypertension over the course of follow-up.35-39 Some
studies have stated that HAART may induce hypertension through hardening of the
vessel walls,37 39 however others report minimal effects. 36 38 In our study, those on
HAART had a small decrease in SBP (-2.1 ± 0.1) and an increase in DBP (7.7 ± 0.4). The
obese individuals in our study had a higher overall mean for systolic and DBP, and larger
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increases in SBP. Both the obese and overweight DBP levels were roughly the same over
time.
The results of our study could be validated by several justifications. First, it has
been reported that obesity is associated with improved outcomes and survival in patients
on hemodialysis, pneumonia, heart transplant, renal failure and liver cirrhosis.75
Therefore, the immune recovery afforded to HIV-infected individuals with higher BMI
have with CD4 count over time could explain why obese individuals have larger
increases in fasting blood glucose and HDL. Secondly, a potential confounder in all
studies evaluating this question is the association between weight loss and untreated HIVinfection is called reverse causality. An example of reverse causality is when the normal
weight category consist of individuals who were normal weight pre-diagnosis, and those
who were overweight but lost weight because of HIV-infection in the period preceding
their diagnosis, or when obese category includes individuals who lost weight before their
diagnosis and were considered overweight at diagnosis.24
To prevent the possibility of reverse causality affecting the validity of our results,
height and weight was collected within three months of diagnosis. If reverse causality is
contributing to the association between BMI and cardiovascular disease risk markers,
then the BMI characteristics of the source population are likely important. As HIV is
diagnosed at an earlier stage, before wasting sets in, the HIV-infected population is
similar to the general population with respect to BMI. In our study population the mean
BMI was 27.4 kg/m2, and overweight and obesity prevalence was 30% and 26.8%, which
is similar to the prevalence of overweight (35.4%) and obesity (31.5%) in general HIVuninfected population in South Carolina.19 The characteristics of the study population in
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this report were similar for all HIV-infected individuals in the entire state of South
Carolina, with respect to race (Black: 74.2% versus 76%) and mode of transmission
(MSM: 33.1% versus 37.1%).62 Given the similarities between our study cohort and the
overall HIV-infected population in South Carolina, it is unlikely that reverse causality
significantly impacted our results.
This study has some limitations. First, the treatment variables only measured
whether individuals received HAART, cholesterol medication, diabetic medication, or
blood pressure medication throughout the course of their HIV infection. We did not
assess time spent on these medications. Second, we were unable to make an assumption
that included the underweight BMI category. However, past research has shown that
underweight individuals generally are not associated with increased chances of diabetes,
hypertension or dyslipidemia compared to other BMI categories, although some have
reported that underweight may be associated with risk of developing these diseases.
Third, the alcohol use and drug use variables only captured whether individuals were
socially participating in these factors and not the frequency of use. Fourth, our population
consisted of mostly black HIV-infected individuals and the results may not be
generalizable to other populations. Finally, there is the possibility of residual
confounding such as measurement error of a CD4.
This study has several strengths. First, we explored the post-HAART longitudinal
association between BMI at baseline and cardiovascular risk markers in a southern state.
Second, unlike previous research, we adjusted for many potential confounders including
delayed entry into HIV medical care and use of case management. Entry into HIV
medical care is imperative for access to antiretroviral therapy and facilitates the delivery
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of important prevention education to reduce HIV transmission. In addition, retention in
care is critical to monitor response to therapy. Finally, this investigation includes fourteen
years of follow-up (i.e. those diagnosed in 1997) allowing us to assess the cardiovascular
disease risk markers over a long period. Third, our population of individuals with
different stages of HIV disease, allows us to determine if the relationship under study
exists in HIV-infected individuals with different levels of immune impairment.
The results of this study revealed that HIV-infected individuals who were obese at
diagnosis had greater decreases in fasting blood glucose and larger increases in HDL over
time when compared to HIV-infected individuals who were overweight at diagnosis.
Although higher BMI is associated with improved cardiovascular risk markers among
this HIV-population, providers should monitor weight at diagnosis due to its correlation
with inflammation. Because BMI plays an important role in causing metabolic
abnormalities in non-HIV populations and because BMI at diagnosis may be an important
factor in predicting the effects of HIV and treatment on metabolic abnormalities,
additional studies are needed to evaluate markers of inflammation over time, particularly
among different HIV-infected populations.
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Table 6.1: Baseline characteristics of South Carolina HIV positive individals diagnosed between
1997 and 2010 by Body Mass Index (BMI) category.
Characteristic
Overall
Normal
Overweight
Obese
Pa
(n=396)
(n=171)
(n=119)
(n=106)
Body Mass Index
27.4 ± 6.3
22.3 ± 1.8
27.2 ± 1.5
35.9 ± 5.2
<0.001
Age
35.1 ± 10.6
34.5 ± 11.5
36.1 ± 9.5
34.5 ± 10.2
0.378
Gender
Male
245 (61.9%)
126 (73.7%)
78 (65.6%)
41 (38.7%)
Female
149 (37.6%)
44 (25.7%)
41 (34.5%)
64 (60.4%)
Transgender
2 (0.5%)
1 (0.6%)
1 (0.9%)
<0.001
Race
White, non-Hispanic
92 (23.2%)
38 (22.2%)
28 (23.6%)
26 (24.5%)
Black, non-Hispanic
294 (74.2%)
127 (74.3%)
88 (74.0%)
79 (74.5%)
Hispanic
3 (0.8%)
2 (1.2%)
1 (0.8%)
Other
1 (0.3%)
1 (0.8%)
Unknown
6 (1.5%)
4 (2.3%)
1 (0.8%)
1 (1.0%)
0.899
Marital Status
Single
242 (61.1%)
111 (64.9%)
71 (59.7%)
60 (56.6%)
Married
47 (11.9%)
15 (8.8%)
19 (16.0%)
13 (12.3%)
Divorced
70 (17.7%)
25 (14.6%)
18 (15.1%)
27 (25.5%)
Widowed
14 (3.5%)
7 (4.1%)
5 (4.2%)
2 (1.9%)
Partnered
21 (5.3%)
12 (7.0%)
6 (5.0%)
3 (2.8%)
Unknown
2 (0.5%)
1 (0.6%)
1 (0.9%)
0.166
Education
High School Diploma
140 (35.3%)
61 (35.6%)
45 (37.8%)
34 (32.1%)
Associate Degree
23 (5.8%)
8 (4.7%)
4 (3.4%)
11 (10.4%)
Bachelor Degree
24 (6.1%)
6 (3.5%)
8 (6.7%)
10 (9.4%)
Master’s Degree
9 (2.3%)
4 (2.3%)
3 (2.6%)
2 (1.9%)
Doctorate Degree
3 (0.8%)
2 (1.2%)
1 (0.8%)
No HS Diploma
63 (15.9%)
34 (19.9%)
13 (10.9%)
16 (15.1%)
Unknown
134 (33.8%)
56 (32.8%)
45 (37.8%)
33 (31.1%)
0.207
Insurance
Medicare
70 (17.7%)
33 (19.3%)
19 (16.0%)
18 (17.0%)
Medicaid
43 (10.9%)
17 (9.9%)
10 (8.4%)
16 (15.1%)
Private Insurance
96 (24.2%)
30 (17.6%)
35 (29.4%)
31 (29.3%)
None
187 (47.2%)
91 (53.2%)
55 (46.2%)
41 (38.7%)
0.064
Followed by Case Manager
Yes
170 (42.9%)
82 (47.9%)
44 (37.0%)
44 (41.5%)
No
226 (57.1%)
89 (52.1%)
75 (63.0%)
62 (58.5%)
0.170
Alcohol Use
Yes
241 (60.9%)
117 (68.4%)
73 (61.3%)
51 (48.1%)
No
138 (34.8%)
49 (28.7%)
42 (35.3%)
47 (44.3%)
Unknown
17 (4.3%)
5 (2.9%)
4 (3.4%)
8 (7.6%)
0.017
Smoking
Yes
217 (54.8%)
114 (66.7%)
63 (53.0%)
40 (37.7%)
No
162 (40.9%)
52 (30.4%)
53 (44.5%)
57 (53.8%)
Unknown
17 (4.3%)
5 (2.9%)
3 (2.5%)
9 (8.5%)
<0.001
Drug Use
Yes
141 (35.6%)
72 (42.1%)
44 (37.0%)
25 (23.6%)
No
237 (59.8%)
94 (55.0%)
71 (59.7%)
72 (67.9%)
Unknown
17 (4.6%)
5 (2.9%)
4 (3.3%)
9 (8.5%)
0.010
Mode of Transmission
Heterosexual
221 (55.8%)
81 (47.4%)
66 (55.5%)
74 (69.8%)
MSM
131 (33.1%)
72 (42.1%)
38 (31.9%)
21 (19.8%)
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IDU
NIR/NRR
Delayed entry into care
<3 months
≥3 months
HAART use
Yes
No
Diabetic medication
Yes
No
Cholesterol medication
Yes
No
BP medication
Yes
No
CD4 count at diagnosis

20 (5.1%)
24 (6.1%)

8 (4.7%)
10 (5.9%)

7 (5.9%)
8 (6.7%)

5 (4.7%)
6 (5.7%)

0.013

171 (43.2%)
225 (56.8%)

78 (45.6%)
93 (54.4%)

39 (32.8%)
80 (67.2%)

54 (50.9%)
52 (49.1%)

0.016

349 (88.1%)
47 (11.9%)

161 (94.2%)
10 (5.8%)

109 (91.6%)
10 (8.4%)

95 (89.6%)
11 (10.4%)

0.109

36 (9.1%)
360 (90.9%)

11 (6.4%)
160 (93.6%)

8 (6.7%)
111 (93.3%)

17 (16.0%)
89 (84.0%)

0.015

62 (15.7%)
334 (84.3%)

24 (14.0%)
147 (86.0%)

20 (16.8%)
99 (83.2%)

18 (17.0%)
88 (83.0%)

0.741

143 (36.1%)
253 (63.9%)
499.3 ± 255.2

50 (29.2%)
121 (70.8%)
448.4 ± 229.1

44 (37.0%)
75 (63.0%)
498.4 ± 231.1

49 (46.2%)
57 (53.8%)
575.6 ± 296.2

0.016
0.019

4.1 ± 0.9
95.8 ± 40.4

4.2 ± 0.9
90.8 ± 27.0

4.2 ± 0.9
92.4 ± 20.4

3.8 ± 0.9
106.6 ± 63.8

<0.001
0.102

46.3 ± 19.1
113.4 ± 37.2

46.2 ± 21.6
94.4 ± 27.6

40.2 ± 4.4
125.4 ± 49.7

49.2 ± 21.7
123.4 ± 35.4

0.652
0.131

126.9 ± 16.3

125.7 ± 15.2

124.8 ± 16.9

130.7 ± 17.0

0.134

Log HIV VL at diagnosis
Fasting blood glucose at
diagnosis
HDL at diagnosis
LDL at diagnosis
SBP at diagnosis
DBP at diagnosis
81.2 ± 11.3
80.2 ± 11.6
80.5 ± 12.4
83.3 ± 9.8
0.281
Abbreviations: MSM, men who have sex with men; IDU, injecting drug user; NIR/NRR, no
identified/reported risk factor; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic
blood pressure; DBP, diastolic blood pressure
NOTE: Mean and standard deviation are shown for Body mass Index, Age, CD4 count at diagnosis, HIV
VL at diagnosis.
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2).
Underweight individuals were excluded because numbers were too few for meaningful analysis.
- Transgender was not included in the table.
a
Comparison between baseline BMI strata
**Insurance – None: No insurance/ADAP Program
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Table 6.2: Mixed Model Analysis of the association between Body Mass Index
(BMI) and cardiovascular disease risk markers among HIV-infected
individuals diagnosed in South Carolina between 1997-2010.
Model
Parameter
Standard
Pa
Estimate
Error (SE)
Blood Glucose
Full Model
0.3
0.007
<0.001
Time
BMI
10.9
0.2
<0.001
Obese
9.6
0.2
<0.001
Overweight
*
*
*
Normal
time*BMI
-0.5
0.01
<0.001
time*Obese
-0.3
0.01
<0.001
time*Overweight
*
*
*
time*Normal
HDL
Full Model
0.2
0.008
<0.001
Time
BMI
-4.7
0.2
<0.001
Obese
3.9
0.2
<0.001
Overweight
*
*
*
Normal
time*BMI
0.2
0.01
<0.001
time*Obese
0.06
0.01
<0.001
time*Overweight
*
*
*
time*Normal
LDL
Full Model
-1.2
0.007
<0.001
Time
BMI
-2.7
0.2
<0.001
Obese
3.0
0.2
<0.001
Overweight
*
*
*
Normal
time*BMI
0.2
0.01
<0.001
time*Obese
-0.2
0.01
<0.001
time*Overweight
*
*
*
time*Normal
SBP
Full Model
0.04
0.008
<0.001
Time
BMI
1.8
0.2
<0.001
Obese
7.0
0.2
<0.001
Overweight
*
*
*
Normal
time*BMI
-0.2
0.02
<0.001
time*Obese
-0.1
0.01
<0.001
time*Overweight
*
*
*
time*Normal
DBP
Full Model
-0.3
0.008
<0.001
Time
BMI
-0.9
0.2
<0.001
Obese
-2.1
0.2
<0.001
Overweight
*
*
*
Normal
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time*BMI
time*Obese
time*Overweight
time*Normal

0.3
0.2
*

0.02
0.01
*

<0.001
<0.001
*

Abbreviations: SE, standard error; SBP, systolic blood pressure; DBP, diastolic blood
pressure
NOTE: * Normal BMI category - reference group. The parameter estimates represent the
difference in the adjusted mean CD4 count by BMI category. Those overweight has higher
mean CD4 counts. b Comparison between baseline BMI categories.
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2)
- Underweight individuals were excluded because numbers were too few for meaningful
analysis.
- Models adjusted for, baseline CD4 count, CD4 count over time baseline VL, viral load
over time, age, fasting blood glucose over time, HDL and LDL over time, SBP and DBP
over time, gender, race, mode of transmission and treatment, alcohol use, smoking use,
drug use, marital status, education, and type of insurance, case management, delayed entry
into care, HAART use, cholesterol medication use, blood pressure medication use, and
diabetes medication use.
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Table 6.3: Mixed Model Analysis of the interaction between Body Mass Index (BMI) and highly
active antiretroviral therapy (HAART) use and its association with cardiovascular disease risk
markers among HIV-infected individuals diagnosed in South Carolina between 1997-2010.
Pa
Model
Parameter Estimates (SE)
Blood Glucose
BMI*HAART use
4.5 (0.5)
<0.001
Obese*Yes
*
*
Obese*No
-6.7 (0.6)
<0.001
Overweight *Yes
*
*
Overweight *No
HDL
BMI*HAART use
9.9 (0.5)
<0.001
Obese*Yes
*
*
Obese*No
-8.4 (0.6)
<0.001
Overweight *Yes
*
*
Overweight *No
LDL
BMI*HAART use
-18.9 (0.5)
<0.001
Obese*Yes
*
*
Obese*No
-13.2 (0.6)
<0.001
Overweight *Yes
*
*
Overweight *No
SBP
BMI*HAART use
-5.5 (0.5)
<0.001
Obese*Yes
*
*
Obese*No
1.0 (0.7)
0.113
Overweight *Yes
*
*
Overweight *No
DBP
BMI*HAART use
-9.3 (0.5)
<0.001
Obese*Yes
*
*
Obese*No
-12.3 (0.7)
<0.001
Overweight *Yes
*
*
Overweight *No
Abbreviations: SE, standard error; SBP, systolic blood pressure; DBP, diastolic blood pressure
NOTE: * Normal BMI category and No HAART use- reference groups.
The parameter estimates represent the difference in the adjusted mean CD4 count by BMI category.
Those overweight has higher mean CD4 counts. b Comparison between baseline BMI categories.
- Normal (≤ 24.9 kg/m2), Overweight (25.0-29.9 kg/m2), Obese (≥ 30.0 kg/m2)
- Underweight individuals were excluded because numbers were too few for meaningful analysis.
- Models adjusted for, baseline CD4 count, CD4 count over time baseline VL, viral load over time, age, fasting blood
glucose over time, HDL and LDL over time, SBP and DBP over time, gender, race, mode of transmission and
treatment, alcohol use, smoking use, drug use, marital status, education, and type of insurance, case management,
delayed entry into care, HAART use, cholesterol medication use, blood pressure medication use, and diabetes
medication use.
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Figure 6.1: Adjusted fasting blood glucose means by BMI category
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Figure 6.2: Differences in the adjusted fasting blood glucose means by BMI category

95

Adjusted HDL Mean by BMI Category

60

Adjusted Mean HDL

50

40
Norm al
Overweight

30

Obes e

20

10

0

Visit 1

Visit 14

Visit 28

Visit 42

Visit 54

Normal

39.4

40.6

41.9

43.3

44.4

Overweight

42.7

44.3

45.9

47.6

49

Obese

36.5

39.8

43.3

46.7

49.7

Figure 6.3: Adjusted HDL means by BMI category

Differences in Adjusted HDL Mean (Compared to Normal
Category)

Differences in Adjusted Mean HDL

6
5
4
3
2
Overweight

1

Obese

0
-1
-2
-3
-4

Visit 1

Visit 14

Visit 28

Visit 42

Visit 54

Overweight

3.3

3.7

4

4.3

4.6

Obese

-2.9

-0.8

1.4

3.4

5.3

Figure 6.4: Differences in the adjusted HDL means by BMI category
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Figure 6.5: Adjusted LDL means by BMI category
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Figure 6.6: Differences in the adjusted LDL means by BMI category
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Figure 6.7: Adjusted SBP means by BMI category
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Figure 6.8: Differences in the adjusted SBP means by BMI category
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Figure 6.9: Adjusted DBP means by BMI category
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CONCLUSIONS
As the prevalence of overweight and obesity continues to increase among HIVinfected individuals and as treated HIV-infected individuals continue to be plagued by
metabolic abnormalities, additional research is needed to study this relationship among
different HIV-infected populations and determine which factors are involved in creating
these results. In this study, there were significant differences in CD4 count over time
between overweight and obese individuals when compared to normal weight individuals.
Overweight HIV-infected individuals, had larger increases in CD4 count and HDL over
time and larger decreases in DBP over time. Obese HIV-infected individuals had larger
increases in fasting blood glucose and SBP, which is indicative of the effects of obesity in
causing inflammation. Female HIV-infected individuals had larger increases in CD4
count over time compared to males. The difference between females and males could be
explained gynecological factors such as menopause or hormone replacement therapy.
However, this study did not assess any gynecological factors and their association with
progression of HIV.
HIV data is generally non-linear and the statistical analyses chosen are very
essential to accurately estimate differences between groups. Our study used a mixed
model analysis which allowed us to choose the best covariance structure that fit with the
data. Spatial power was the covariance structure fitted to the mixed model analysis
because it allows unequal measurements of data among individuals in the study. Future

100

researchers could use non-linear mixed model analyses to obtain better estimates for this
relationship.
Several limitations affected our study. First, the secular change of CD4 count is
impacted as more HIV-infected individuals are prescribed HAART and medication
efficacy has increased, which could potentially attenuate the associations.22 Second, our
population consisted of mostly black HIV-infected individuals and the results may not be
generalizable to other populations. Third, we were unable to make an assumption that
included the underweight BMI category. However, past research has shown that
underweight individuals generally are not associated with increased chances of diabetes,
hypertension or dyslipidemia compared to other BMI categories, although some have
reported that underweight may be associated with risk of developing these diseases.
Fourth, the treatment variables only measured whether individuals received HAART,
cholesterol medication, diabetic medication, or blood pressure medication throughout the
course of their HIV infection. We did not assess time spent on these medications. Fifth,
there is the possibility of residual confounding. Sixth, we did not collect any information
on gynecological factors (i.e. contraception use, menopause status) that could potentially
confound our results. Finally, the alcohol use and drug use variables only captured
whether individuals were socially participating in these factors and not the frequency of
use.
This study has several strengths. First, we explored the post-HAART longitudinal
association between BMI at baseline and cardiovascular risk markers in a southern state.
Second, unlike previous research, we adjusted for many potential confounders including
delayed entry into HIV medical care and use of case management. Entry into HIV
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medical care is imperative for access to antiretroviral therapy and facilitates the delivery
of important prevention education to reduce HIV transmission. In addition, retention in
care is critical to monitor response to therapy. Finally, this investigation includes fourteen
years of follow-up (i.e. those diagnosed in 1997) allowing us to assess the cardiovascular
disease risk markers over a long period. Third, our population of individuals with
different stages of HIV disease, allows us to determine if the relationship under study
exists in HIV-infected individuals with different levels of immune impairment.
In all, overweight and obese HIV-infected individuals have different associations
with markers for HIV progression and cardiovascular disease risk. The causes of these
associations are multifactorial and additional research should focus the interaction of
these sources to understand the biological differences between overweight and obese
HIV-infected individuals. Furthermore, this study illustrates the importance and the
ability of BMI to predict response to treatment and potential long-term effects of the
disease and medications.
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Appendix A: Protection of Human Subjects
Target Population
The target population for this proposal was individuals who were HIV-positive.
Medical records from the Ryan White Clinic were reviewed for this study. The majority
of the clients served in the Ryan White Clinic in South Carolina were male (60%),
African American (73%), and aged 25-44 (50.7%).35 For inclusion in the study, adults
were at least 18 years of age, diagnosed with HIV from January 1, 1997-December 31,
2010 in the state of South Carolina and had at least one confirmatory Western Blot, had
weight and height measured within three months of HIV diagnosis, and those with at
least 1 follow-up appointment after BMI was recorded at diagnosis. HIV-positive
individuals who are pregnant, or have taken either hypertensive, diabetic or cholesterol
medication were excluded from this study. A total of 400 HIV-positive adults were
included in this study. The sample size was determined using SAS 9.2 power analysis for
ANOVA design. Given that the relationship under study is a relatively understudied area
of research among HIV patients, this particularly study was necessary.
Recruiting Plans
Recruitment of individuals for this proposal was not necessary because the
investigators used data that was already in existence. Only de-identified data were
collected to prevent from exposing any private information.
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Existing Data/Samples
Investigators of this proposal used existing data from medical records which are
located in Ryan White HIV/AIDS Clinic to acquire the data listed in the data abstraction
sheet. Although the medical records contained direct identifiers, none of that information
was collected. The data was recorded in Epi Data with the pre-approved variables listed
on the data abstraction sheet and exported into SAS.
Consent/Assent
For this proposal, consent from patients of the Ryan White Clinic was necessary
because the investigators used data that was already in existence. Only de-identified data
were collected to prevent from exposing any private information.
Potential Risks
We believe that there was minimal risk to study participants, because information
that was collected did not contain any personal information and the investigator that
collected the data was required to keep that information confidential. The proposed
research fell under Exemption 4 (AIM 1, AIM 2, and AIM 3) and Expedited Review
Category 5 (AIM 1, AIM 2, and AIM 3). An application for this study was approved by
the University of South Carolina, Institutional Review Board. All study personnel were
trained and certified in federal and state policies regarding the protection of human
subjects’ participation in research (CITI). The human subjects data used for AIMS 1, 2,
and 3 of this proposal were part of the medical records from the Ryan White Clinic.
Careful consideration was taken to ensure the anonymity of study participants. No
individual will be identified in any publications resulting from this study. Furthermore,
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we feel by blocking access to sensitive charts (i.e. charts from students and faculty of the
University of South Carolina), further protected the confidentiality of all patients.
Potential Benefits
There was no direct benefit to participants as a result of this study. However, the
information obtained from this study will add to the body of scientific knowledge about
this important area of research. This proposed research will also provide information that
can be used to inform intervention decisions, including when to initiate therapy and
whether monitoring BMI could be a useful marker in assessing the success of such
therapy, particularly in resource-limited countries. Given that the rates of obesity are
increasing among HIV patients, the results of this study could potentially help in
understanding the factors associated with increased rates of disease progression and
cardiovascular risk in HIV patients. Using medical records enabled this research to
provide a more comprehensive assessment of this relationship. These findings can
provide the framework for clinicians to develop more appropriate HIV treatment
strategies that can ultimately allow HIV-positive individuals to live longer.
Confidentiality
As mandated by the state and the Institutional Review Board (IRB) of the
University of South Carolina, authorized persons trained in the Health Insurance
Portability and Accountability Act (HIPAA) confidentiality procedures retrieved the data.
Study investigators were required to abide by the guidelines set forth by the state and
school with regards to the security and confidentiality of the data. To further protect
confidentiality, access to patient charts who were deemed sensitive (i.e. students and
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faculty of USC) were blocked. The principle investigator was the only person collecting
the data. Unique identifiers were created for each patient. The definition of the unique
identifier was located within the data abstraction sheet. The unique identifier and medical
record for each patient was recorded on the patient list file. The data file and the patient
list file was kept in a secure location, under lock and key at the Ryan White Clinic, under
the supervision of Shirley Patterson. Only Mrs. Patterson and I had access to the data
files. The data was not stored on a local hard drive or network drive. However, all data
analysis by the investigators was conducted at University of South Carolina School of
Public Health using password-protected computers once the data was exported to SAS.
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